CVCT

December 9 -11, 2024
The Mayflower Hotel, Washington DC

SCIENTIFIC PROGRAM

21st Global Cardio Vascular Clinical Trialists Forum

FACULTY

ACADEMY

1. Kirkwood Adams (Chapel Hill, NC, USA)
2. Demilade Adedinsewo (Jacksonville, FL, USA)
3. Anubha Agarwal (St Louis, MI, USA)
4. Alberto Aimo (Pisa,ITA)
5. Rasha al Lamee (London UK)
6. Lisa Anderson (London, UK)
7. Jason Andrade (Vancouver, CAN)
8. Elena Arbelo (Barcelona, ESP)
9. Samir Naeem Assaad (Alexandria,EGY)
10. Michel Azizi (Paris, FRA)
11. Christie Ballantyne (Houston, TX, USA)
12. Marko Banovic (Belgrade, RS)
13. Huiman Barnhart (Durham, NC, USA)
14. Ankeet Bhatt (Boston, MA, USA)
15. Tor Biering-Sorenson (Copenhagen, DEN)
16. Jan Biegus (Wroclaw, POL)
17. Sinjini Biswas (Melbourne, AUS)
18. Donato Bonifazi (Pavia, ITA)
19. Stefan Blankenberg (Hamburg, GER)
20. Ron Blankstein (Boston, MA, USA)
21. Erin Bohula (Boston, MA, USA)
22. Claus Bolte (Ex-Swissmedic, Basel, CH)
23. Marc Bonaca (Denver, CO, USA)
24. Rossana Bongianino (Pavia, ITA)
25. Guillermo Bortman (Buenos-Aires; ARG)
26. Louise Bowman (Oxford, UK)
27. Biykem Bozkurt (Houston, USA)
28. Bram Ramjiawan (Winnipeg, CAN)
29. Kelley Branch (Seattle, WA, USA)
30. Richard Bulbulia (Oxford, UK)
31. Daniel Burkhoff (New York, NY, USA)
32. Neel Butala (Denver, CO, USA)
33. Jawad H Butt (Copenhagen, DEN)
34. Javed Butler (Dallas, TX, USA)
35. Seemant Chaturvedi (Baltimore, MA, USA)
36. Steven Lok Fai Cheang (Nanjing, CHN)
37. Kelly Chin (Dallas, TX, USA)
38. Leslie Cho (Cleveland, OH, USA)
39. Karen Christman (San Diego, CA,USA)
40. David Cohen (New York, NY, USA)
41. Maria Rosa Costanzo (Naperville, IL, USA)
42. Gad Cotter (Momentum LLC, USA)
43. Jonathan Cunningham (Boston, MA, USA)
44. Don Cutlip (Boston, MA, USA)
45. Nikolaos Dagres (Berlin, GER)
46. Kevin Daly (Boston, MA, USA)
47. Thomas Deering (Atlanta, GA, USA)
48. Christian Delles (Glagow, UK)
49. Milind Desai (Cleveland, OH, USA)
50. Asita de Silva (Kelaniya, LK)
51. Ron Do (New York, NY, USA)
52. Kieran Docherty (Glasgow, UK)
53. Pamela Douglas (Durham, NC, USA)
54. Issa Dahabreh (Boston, MA, USA)
55. Anne Dubin (Palo Alto, CA, USA)
56. Marc Dweck (Edinburgh, UK)
57. Chadli Dziri (Tunis, TUN)
58. Anastase Dzudie (Douala, CM)
59. Perry Mark Elliott (London, UK)
60. Brendan M. Everett (Boston, MA, USA)
61. Joao Ferreira (Porto, POR)
62. Enrico Ferro (Boston, MA, USA)
63. Mona Fiuzat (Washington, DC, USA)
64. Thomas Forbes (Hollywood, FL, USA)
65. Jimmy Ford (Chapel Hill, NC, USA)
66. Marianna Fontana (London, UK)
67. Habib Gamra (Sousse, TN)
68. Michael Gibson (Boston, MA, USA)
69. Nicolas Girerd (Nancy, FRA)
70. Anne Goldberg (St Louis, MO, USA)
71. Mardi Gomberg-Maitland (Washington, USA)
72. Sascha Goonewardena (Ann Arbor, MI, USA)
73. Celina Gorre (Women at Heart, USA)
74. Christopher Granger (Durham, NC, USA)
75. Jennifer Green (Durham, NC, USA)
76. Barry Greenberg (San Diego, CA, USA)
77. John Gregson (London, UK)
78. Aakriti Gupta (Los Angeles, CA, USA)
79. Edip Gurol (Boston, MA, USA)
80. Rebecca Hahn (New York, NY, USA)
81. Joshua Hare (Miami, FL, USA)
82. Josephine Harrington (Durham, NC, USA)
83. Paul Hassoun (Baltimore, MA, USA)
84. Hiddo Lambers Heerspink (Groningen, NED)
85. Lars Hemkens (Basel, CH)
86. Kevin Hill (Durham, NC, USA)
87. Gerhard Hindricks (Leipzig, GER)

88. Kimberly Hong (San Diego, CA, USA)
89. Marc Humbert (Paris, FRA)
90. John Hummel (Columbus, OH, USA)
91. Sneha Jain (Stanford, CA, USA)
92. Jim Januzzi (Boston, MA, USA)
93. Meg Jardine (Sydney, AUS)
94. Jesper Jensen (Copenhague, DEN)
95. Chokri Jeribi (Eshmoun, TUN)
96. Mariell Jessup (Philadelphia, PA, USA)
97. Michelle Johansen (Baltimore, MA, USA)
98. Sanjit Jolly (Hamilton, CAN)
99. Dan Judge (Charleston, SC, USA)
100. Peter Juni (Oxford, UK)
101. Shahzeb Khan (Chicago, IL, USA)
102. Pia Kamstrup (Herlev, DEN)
103. Abdoul Kane (Dakar, SN)
104. Navin Kapur (Boston, MA, USA)
105. Kazuomi Kario (Tochigi, JPN)
106. Juan Pablo Kaski (London, UK)
107. Josef Kautzner (Prague, CZ)
108. Sanjay Kaul (Los Angeles, CA, USA)
109. Masataka Kawana (Stanford, CA, USA)
110. Steve Kawut (Philadelphia, PEN, USA)
111. Rohan Khera (New Haven, CT, USA)
112. Paulus Kirchhof (Hambourg, GER)
113. Eric Klug (Sandton, ZAF)
114. Masatake Kobayashi (Tokyo, JPN)
115. Wolfgang Koenig (Munich, GER)
116. Ahmed Kolkailah (Dallas, TX, USA)
117. Agnes Koczo (Pittsburgh, PA, USA)
118. Vijay Kunadian (Newcastle upon Tyne, UK)
119. Valentina Kutyifa (Rochester, NY, USA)
120. Carolyn Lam (Singapore, SIN)
121. Matthew Lee (Glasgow, UK)
122. Margrét Leósdóttir (Malmö, SWE)
123. Jennifer Li (Durham, NC, USA)
124. Xinli Li (Nanjing, CHN)
125. Jerker Liljestrand (Stockholm, SWE)
126. Michael Lincoff (Cleveland, OH, USA)
127. Brian Lindman (Nashville, TN, USA)
128. Christopher Lindsell (Durham, NC, USA)
129. Dominik Linz (Maastricht, NED)
130. Angela Lorts (Cincinnati, OH, USA)
131. Renato Lopes (Durham, NC, USA)
132. Darren McGuire (Dallas, TX, USA)
133. Vallerie McLaughlin (Ann Arbor, MI, USA)
134. John McMurray (Glasgow, UK)
135. Christina Magnussen (Hamburg, GER)
136. Nassir Marrouche (Tulane, LA, USA)
137. Brad Maron (Baltimore, MA,USA)
138. Martin Maron (Boston, MA, USA)
139. Alison Marsden (Stanford, CA, USA).
140. Ahmad Masri (Portland, OR, USA)
141. Alexandre Mebazaa (Paris, FRA)
142. Guiomar Mendieta (Madrid, ESP)
143. Felipe Martinez (Cordoba, ARG)
144. Kaitlin Mayne (Oxford, UK)
145. Roxana Mehran (New York, NY, USA)
146. Philippe Ménasché (Paris, FRA)
147. Robert Mentz (Durham, NC, USA)
148. Markus Meyer (Minneapolis, MN, USA)
149. Shelley Miyamoto (Denver, CO, USA)
150. Raul Moreno (Madrid, ESP)
151. Amy Mottl (Chapel Hill, NC, USA)
152. Ramesh Nadarajah (Leeds, UK)
153. Ann Marie Navar (Dallas, TX, USA)
154. Ian Neeland (Dallas, TX, USA)
155. Brendon Neuen (Sydney, AUS)
156. David Newby (Edinburgh, UK)
157. Borge Nordestgaard (Copenhagen, DEN)
158. Mpiko Ntsekhe (Cape Town, SA)
159. Ntobeko Ntusi (Cape Town, ZAF)
160. Chris O'Connor (Washington, DC, USA)
161. Michelle O'Donoghue (Boston MA, USA)
162. Iacopo Olivotto (Trieste, ITA)
163. Joanna Osmanska (Glasgow, UK)
164. Maria Pabon (Boston, MA, USA)
165. Milton Packer (Dallas, TX, USA)
166. Elfriede Pahl (Chicago, IL, USA)
167. Ambarish Pandey (Dallas, TX, USA)
168. Sahil Parikh (Boston, MA, USA)
169. Manesh Patel (Durham, NC, USA)
170. Alexander Peikert (Boston, MA, USA)
171. Emerson Perin (Houston, TX, USA)
172. Mark Petrie (Glasgow, UK)
173. Jule Pinter (Würzburg, GER)
174. Bertram Pitt (Ann Arbor, MI, USA),
175. Elke Platz (Boston, MA, USA)
176. Stuart Pocock (London, UK)
177. Silvia Priori (Pavia, ITA)
178. Nawab Qizilbash (Madrid, ESP)
179. Rita Redberg (San Francisco, CA, USA)
180. Nosheen Reza (Philadelphia, PA, USA)
181. Jose Rivero (Boston, MA, USA)
182. Frank Rockhold (Durham, NC, USA)
183. Antony Rodgers (Sydney, AUS)
184. Robert S. Rosenson (New York, NY, USA)
185. Joseph Rossano (Philadelphia, PA, USA)
186. Xavier Rosselló (Madrid, ESP)
187. Peter Rossing (Copenhaguen, DEN)
188. Ethan Rowin (Burlington, MA, USA)
189. Kathy Ruppel (Stanford, CA, USA)

190. Andrea Russo (Cooper Health, USA)
191. Sara Saberi (Ann Arbor, MI,USA)
192. Rajan Saggar (UCLA, CA, USA)
193. Sandeep Sahay (Houston, TX, USA)
194. Clara Saldarriaga (Medellin, COL)
195. Azza Saleh (Cairo, EGY)
196. Rajiv Sankaranarayanan (Liverpool, UK)
197. Naveed Sattar (Glasgow, UK)
198. Ruth Frikke Schmidt (Copenhagen, DEN)
199. Gregory Schwartz (Aurora, CO, USA)
200. Benjamin Scirica (Boston, MA, USA)
201. Mike Sharma (Hamilton, CAN)
202. Leslee Shaw (New York, NY, USA)
203. Sanjiv Shah (Chicago, IL, USA)
204. Abdullah Shehab (Al Ain, UAE)
205. Takeshi Shinkawa (Tokyo, JPN)
206. Cheerag Shirodaria (Oxford, UK)
207. Oksana Shlobin (Washington, DC, USA)
208. Tabassome Simon (Paris, FRA)
209. Gérald Simonneau (Paris, FRA)
210. Olivier Sitbon (Paris, FRA)
211. Mohamed Sobhy (Alexandria, EGY)
212. Scott Solomon (Boston, MA, USA)
213. John Spertus (Kansas City, MO, USA)
214. Paolo Springhetti (Laval, CAN)
215. Randall Starling (Cleveland, OH, USA)
216. Konstantinos Stellos (Francfort, GER)
217. Gregg Stone (New York, NY, USA)
218. Erik Stroes (Amsterdam, NED)
219. Jean Claude Tardif (Montreal, CAN)
220. John Teerlink (San Francisco, CA, USA)
221. Jozine Ter Maaten (Groningen, NED)
222. Jan Tijssen (Amsterdam, NED)
223. Holger Thiele (Leipzig, GER)
224. Maxime Touzot (Owkin, FRA)
225. Rhian Touyz (Montreal, CAN)
226. Jasper Tromp (Singapore, SIN)
227. Katherine Tuttle (Spokane, WA, USA),
228. Jean-Luc Vachiéry (Brussels, BEL)
229. Muthiah Vaduganathan (Boston, MA, USA)
230. Torsten P Vahl (New York, NY, USA)
231. Harriette Van Spall (Hamilton, CAN)
232. Orly Vardeny (Minneapolis, MN, USA)
233. Corey Ventetuolo (Providence, RI, USA)
234. Subodh Verma (Toronto, CAN)
235. Ron Waksman (Washington, DC, USA)
236. Shirley Wang (Los Angeles, CA, USA)
237. Christoph Wanner (Wursburg, GER)
238. Oussama M Wazni (Cleveland, OH, USA)
239. Jason Weatherald (Edmontion, CA)
240. Michael Weber (New York, NY, USA)
241. Matthew Weir (Baltimore, MA, USA)
242. Jeffrey Weitz (Hamilton, CAN)
243. Cindy Westerhout (Edmonton, CAN)
244. Bryan Williams (London, UK)
245. Stephan Windecker (Bern, CH)
246. Lijing Yan (Kunshan, CHN)
247. Robert Yeh (Boston, MA, USA)
248. Seppo Ylä-Herttuala (Kuopio, FIN)
249. Faiez Zannad (Paris, FRA)
250. Wojciech Zareba (Rochester, MN, USA)
251. Shelly Zieroth (Winnipeg, CAN)
252. André Zimerman (Porto Alegre, BRA)
253. Daniel Zimpfer (Vienna, AUT)
254. Sophia Zoungas (Melbourne, AUS)

JOURNAL/MEDIA

255. Michael Basson (Nature Medicine, USA)
256. Robert Bonow (JAMA Cardiology, USA)
257. Flavia Geraldes (Lancet, UK)
258. Harlan Krumholz (JACC, USA)
259. Jane Leopold (NEJM, Boston, USA)
260. Stuart Spencer (Lancet, UK)
261. Chloe Wilson (Lancet, UK)
262. Ron Winslow (Ex Wall Street Journal, USA)

INDUSTRY

263. Cheryl Abbas (Novartis, USA)
264. Siddique Abbasi (Amgen, USA)
265. Philip Adamson (CVRx, USA)
266. Eric Adler (Lexeo Therapeutics, USA)
267. Ryan Ahern (Truveta, USA)
268. Dom Alloco (Shockwave Medical, USA)
269. Sangeetha Anand (CSL Vifor, SWI)
270. Sameer Bansilal (Alnylam, USA)
271. Lance Bates (Boston Scientific, USA)
272. Craig Basson (BitterrootBio, USA)
273. Arnaud Bastien (BMS, USA)
274. Lauren Bataille (Astrazeneca, USA)
275. Nani Bhalla (BMS, USA)
276. Jenny Blau (AstraZeneca, USA)
277. Maria Borentain (Bayer, GER)
278. Anna Borodovsky (Alnylam, USA)
279. Gabriel Brooks (Solid Biosenses, USA)
280. Kristine Buchholtz (Novonordisk, DEN)
281. Mathijs Bunck (Eli Lilly, USA)
282. Adam Castano (BridgeBio, USA)
283. Martine Clozel (Idorsia, CH)
284. Jennifer Costello (Bristol-Myers-Squibb, USA)
285. Michael Cooreman (Inventiva, FRA)
286. Martin Cowie (AstraZeneca, UK)

287. Bjorn Dahlof (Cereno, SWE)
288. CQ Deng (United Therapeutics, USA)
289. Andrea Dennis (Perspectum, GBR)
290. Efthymios Deliargyris (Cytosorbent, USA)
291. Nancy Dreyer (Dreyer strategies, USA)
292. Eric Ducker (XyloCor, USA)
293. Richard Dujmovic (Boston Scientific, USA)
294. Jason Duran (CRISPR Therapeutics)
295. Zubin Eapen (Element Science, USA)
296. Jay Edelberg (Prolaio, USA)
297. Mads Engelmann (Novo Nordisk, DEN)
298. Mackenzie Ford (Merck, USA)
299. Liming Gan (Ribocure Pharmaceuticals, CHN)
300. Nadim Geloo (Abbott, USA)
301. Jyothis George (Amgen, USA)
302. Richard George (Regeneron, USA)
303. Sofia Gerward (NovoNordisk, DEN)
304. Al Gianchetti (Xylocor, USA)
305. Chris Giordano (Tenax Therapeutics, USA)
306. Bruce Given (Arrowhead, USA)
307. Rich Gliklich (OM1, USA)
308. Joe Gogain (Somalogic, USA)
309. Christine Gouillard (US2AI, SIN)
310. Xiaodong Guan (Beijing, CHN)
311. Jennifer Hellawell (Arrowhead Pharmaceuticals, USA)
312. James Hamilton (Arrowhead Pharmaceuticals, USA)
313. Scott Harris (Altimmune, USA)
314. Sibylle Hauske (Boehringer, GER)
315. Steve Heitner (Cytokinetics, USA)
316. Graeme Hickey (Medtronic, USA)
317. Robert Hillman (Celecor, USA)
318. Brad Horst (Boston Scientific, USA)
319. Christian Hunter (Abbott, USA)
320. Eva Hurt Camejo (Astra Zeneca, USA)
321. Philip Janiak (Corteria, FRA)
322. Peter Kahr (Neurimmune, CH)
323. Takehiko Kaneko, (Heartseed, JPN)
324. John Kastelein (New Amsterdam Pharma, UK)
325. Sekar Kathiresan (Verve Therapeutics, USA)
326. Matthieu de Kelbermatten (Cellprothera, FRA)
327. Kirstie Keller (Additional Ventures, USA)
328. Amit Khera (Verve Therapeutics, USA)
329. So-Young Kim (Bayer, GER)
330. Bettina Kraus (Boehringer, GER)
331. Ethan Korngold (Abbott, USA)
332. Alessandra Lafranconi (Boehringer, GER)
333. Andres Laguna (Novartis, ESP)
334. John Laschinger (Edwards, USA)
335. Franscesca Lawson(Corteria, USA)
336. Charles Lee (AstraZeneca, USA)
337. Marty Lefkowitz (Novartis, USA)
338. Anastasia Lesogor (Novartis, USA)
339. Jennifer Linge (Amra Medical, SWE)
340. Dustin Little (AstraZeneca, USA)
341. Antonio Lopez (Amgen, USA)
342. Steven Lubitz (Novartis, USA)
343. Christian Medom Madsen (Novonordisk, DEN)
344. Fady Malik (Cytokinetics, USA)
345. Serge Masson (Roche, CH)
346. Laura Michael (Lilly, USA)
347. Marie Mide Michelsen (NovoNordisk, DEN)
348. Atif Mohammad (AstraZeneca, USA)
349. Karina Morley (AstraZeneca, SWE)
350. James Moon (MyCardium AI Ltd, UK)
351. Eva Muehlhofer (Bayer, GER)
352. Peter Muntendam (SQInnovation, USA)
353. Masahiro Murakami (Eli Lilly, USA)
354. Gillian Murtagh (Abbott, UK)
355. Manuela Negoita (Medtronic, USA)
356. Christie Nie (Prothena, USA)
357. Stefan Nilsson (Lipigon Pharmaceuticals, SWE)
358. Chris O'Donnell (Novartis, USA)
359. Abena Osei-Wusu (Merck, USA)
360. Shira Perl (AstraZeneca, USA)
361. Duane Pinto (JenaValve, USA)
362. Alexei Plotnikov (Janssen, USA)
363. Jeff Popma (Medtronic, USA)
364. Juergen Prochaska (Boehringer, GER)
365. Ricardo Rocha (Intellia Therapeutics, USA)
366. Lothar Roessig (AskBio-Bayer, GER)
367. Sébastien Roux (Idorsia, CH)
368. Giacomo Ruotolo (Lilly, USA)
369. Nitin Salunke (Supira Medical, USA)
370. Carlos Sanmarco (Roivant, USA)
371. Janarthanan Sathananthan (Boston Scientific, USA)
372. Jonathan Schwartz (RocketPharma, USA)
373. Maria Sejersten Ripa (Novo Nordisk, DEN)
374. Marc Semigran (Edgewise, USA)
375. Thomas Senderovitz (Novo Nordisk, DEN)
376. Lei Shen (Lilly, USA)
377. Chuck Simonton (Abiomed, USA)
378. Dorthe Charlotte Skovgaard (NovoNordisk, DEN)
379. Evan Stein (LIBTherapeutics, USA)
380. Kenneth Stein (Boston Scientific, USA)
381. Dominic Steubl (Boehringer, GER)
382. Karsten Strauß (Olink, SWE)
383. Elena Startseva (Boehringer, GER)
384. Mikhail Sumin (Boehringer Ingelheim, GER)
385. Filip Surmont (AstraZeneca, SWE)

386. Beverly Tang (Starlight Cardiovascular, USA)
387. Thomas Thum (Cardior, GER)
388. Sotirios Tsimikas (Ionis, USA)
389. Alessia Urbinati (Merck, USA)
390. Liron Walsh (Intellia Therapeutics, USA)
391. Daniel Wendt (Cytosorbent, USA)
392. Fred Yang (KBP BioScience, USA)
393. Denise Yates (Novartis, USA)
394. Bryan Young (Regeneron, USA)
395. Dion Zappe (Alnylam, UK)
396. Cordula Zeller (Boehringer, GER)
397. Xue-Qiao Zhao (Regeneron, USA)
398. Larry Zisman (Gossamer, USA)

REGULATORY

399. Ariel Ash-Shakoor (FDA, USA)
400. Rosalyn Adigun (FDA, USA)
401. Mirvat Alasnag (Saudi FDA, KSA)
402. Agustina Bisio (ANMAT, ARG)
403. Donato Bonifazi (EMA, ITA)
404. Rob Califf (FDA, USA)
405. Daniel Canos (FDA, USA)
406. Kenneth Cavanaugh (FDA, USA),
407. Alison Cave (MHRA,UK)
408. John Concato (FDA, USA)
409. Eileen Craig (FDA, USA)
410. Andrew Farb (FDA, USA)
411. Charu Gandotra (FDA, USA)
412. Lydia Glaw (FDA, USA)
413. Laura Higginbotham (FDA, USA)
414. Hylton Joffe (FDA, USA)
415. Rekha Kambhampati (FDA, USA)
416. Yutaku Kaneta (PMDA, JPN)
417. Paul Lee (FDA, USA)
418. Brian Lewis (FDA,USA)
419. Manabu Minami (PMDA, JPN)
420. Chinwe Okoro (FDA, USA)
421. Gabriella Passacquale (EMA, ITA)
422. Ileana Piña (FDA, USA)
423. Jordan Pomeroy (FDA, USA)
424. Ann Punnoose (FDA, USA)
425. Mitch Psotka (FDA, USA)
426. Anindita Saha (FDA, USA)
427. Bindi Shah (FDA,USA)
428. John Sharretts (FDA, USA)
429. Jeff Siegel (FDA, USA)
430. Norman Stockbridge (FDA, USA)
431. Mary Ross Southworth (FDA, USA)
432. Bart van der Schueren (EMA, BEL)
433. George van Hare (FDA, USA)
434. Bernard.Vasseur (FDA, USA)
435. Changfu Wu (FDA, USA)
436. Erica Young (FDA, USA)
437. Bram Zuckerman (FDA, USA)

NIH / PUBLIC HEALTH INSTITUTIONS

438. David Goff (NHLBI, NIH, USA)
439. Rebecca Gottesman (NINDS, NIH, USA)
440. George Mensah (NHLBI,USA)
441. Gail Pearson (NHLBI, NIH, USA)
442. Tiffany Powell-Wiley (NHLBI, NIH, USA)
443. Yves Rosenberg (NHLBI, NIH, USA)

PATIENTS/PATIENTS REPRESENTATIVES

444. Jacqueline Alikhaani (Los Angeles, USA)
445. Sadegh Alikhaani (Los Angeles, USA)
446. Alessia Argiro (Florence ITA)
447. Colleen Brunetti (Pulmonary Hypertension Association, USA)
448. Philip Collis (British Heart Foundation, UK)
449. Magdalena Daccord (FH Europe, CH)
450. Robin Gage (Lakeland, FL, USA)
451. Hanneke Geelhoed (Harteraad, NED)
452. Penilla Gunther (Stockholm, SWE)
453. Nick Hartshorne-Evans (Pumping Marvellous Foundation, UK)
454. Mellanie True Hills (Stop AFib, USA)
455. Nichole Jefferson (Dallas, TX, USA)
456. Anitha John (Washington DC, USA)
457. Trudie Lobban (Heart Rhythm Alliance, London, UK)
458. Isabelle Lousada (Amyloidosis Research Consortium, USA)
459. Steve Macari (Poitiers, FRA)
460. Greg Merritt (Patient Is Partner, Brighton, USA)
461. Caius Ovidiu Mersa (Timișoara, ROM)
462. Rhonda Monroe (Baltimore, MD, USA)
463. Wanda Moore (CCHHE, USA)
464. Juddson Rupp (Charlotte, NC, USA)
465. Lisa Salberg (HCMA, USA)
466. Mariette Verbakel (Nijmegen, NED)

PAYER / ECONOMISTS

467. Mark Chakravarty (NICE, UK)
468. Borislava Mihaylova (London, UK)
469. Benjamin N Rome (Boston, MA, USA)

470. Shaun Rowark (NICE, UK)
471. Abigail Wright (ICER, USA)

MONDAY, DECEMBER 9TH

LUNCH SERVED AT THE MEETING VENUE

ROOM 1

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
REAL WORLD DATA view details >>		MASTER CLASS 1 view details >>		MASTER CLASS 2 view details >>		WIN RATIO view details >>

ROOM 2

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
NEUROCARDIOLOGY view details >>		GENE THERAPY view details >>		CELL THERAPY view details >>		ARTIFICIAL INTELLIGENCE view details >>

ROOM 3

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
WOMEN IN TRIALS view details >>		THROMBOSIS TRIALS CHALLENGING INDICATIONS view details >>		ATRIAL FIBRILLATION view details >>		HF-ELECTRO-PHYSIOLOGY view details >>

ROOM 4

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
HYPERTENSION view details >>		DIABETES – CKD 1 view details >>		DIABETES – CKD 2 view details >>		iCVCT THROMBOSIS FACTOR XI INHIBITORS view details >>

TUESDAY, DECEMBER 10TH

LUNCH SERVED AT THE MEETING VENUE

ROOM 1

7:00 - 8:00	8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
Trials in APAC view details >>	CVCT GOING GLOBAL view details >>		PAH TRIALS 1 view details >>		PAH TRIALS 2 view details >>		PAH TRIALS 3 view details

ROOM 2

7:00 - 8:00	8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
Trials in Africa ME view details >>	GLP1RA in CKM view details >>		PEDIATRIC TRIALS view details >>		PEDIATRIC DEVICES view details >>		BIOLOGICS view details

ROOM 3

7:00 - 8:00	8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
Trials in LATAM view details >>	CV SAFETY view details >>		POST MI DRUG THERAPY view details >>		CORONARY CT view details >>		IMPLEMENTATION TRIALS view details

ROOM 4

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
AMYLOIDOSIS view details >>		CARDIO-MYOPATHIES 1 view details >>		CARDIO-MYOPATHIES 2 view details >>		HFPEF TRIALS view details >>

18:30 - 19:00

KEYNOTE LECTURE BY HYLTON JOFFE

FDA , DIRECTOR OFFICE OF CARDIOLOGY, HEMATOLOGY, ENDOCRINOLOGY AND NEPHROLOGY

WEDNESDAY, DECEMBER 11TH

LUNCH SERVED AT THE MEETING VENUE

ROOM 1

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
OBESITY TRIALS 1 view details >>		HEART FAILURE 1 view details >>		OBESITY TRIALS 2 view details >>		HEART FAILURE 2 view details >>

ROOM 2

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
TRIGLYCERIDE view details >>		LIPOPROTEIN(A) view details >>		CHOLESTEROL view details >>		AORTIC STENOSIS view details >>

ROOM 3

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
iCVCT VALVE view details >>		iCVCT STRUCTURAL HEART view details >>		iCVCT SHOCK view details >>		iCVCT CORONARY view details >>

ROOM 4

8:00 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
GLOBAL REGULATORY SUMMIT view details >>		PATIENT TRIALISTS HEALTH DATA AND DIGITAL TOOLS view details >>		UNDIAGNOSED HEART FAILURE view details >>		BIOMARKER view details >>

Room 1
Monday, December 9, 2024
8:00 -10:30

Real-Worl Data (RWD) - WHAT IT IS, WHY IT'S USEFUL AND WHY CARDIOLOGISTS SHOULD CARE?
Chairpersons : Robert Califf (FDA, USA) & Shirley Wang (Los Angeles, CA, USA)

«There are too many important questions to attempt to answer them all with RCTs, and too little funding» **(Rob Califf, FDA, USA)**

Quantifying/Optimizing RWD reliability.
Rich Gliklich (OM1, USA)

Transparency and clarity of Real-World Evidence
Lars Hemkens (Basel, CH)

How often and in what contexts RWE do findings match RCTs'?
Emulating RCTs with non-randomized RWE Studies.
Shirley Wang (Los Angeles, CA, USA)

How RWD and AI may help trial design and trial results implementation
Ryan Ahern (Truveta, USA)

RWD for investigating patients and conditions not studied in clinical trials, such as studies of the elderly, youth, pregnancy and ethnic minorities.
Rich Gliklich (OM1, USA)

Understanding the RW impact of surrogate endpoints from pivotal trials.
Robert Yeh (Boston, MA, USA)

Can RWD make drugs safer than simply using randomized clinical trials?
Alison Cave (MHRA, UK)

RWD on STEMI management in Africa.
Habib Gamra (Sousse, TN)

RW monitoring of clinical practice. Insight from the Postmarketing Surveillance of Inferior Vena Cava Filters
Enrico Ferro (Boston, MA, USA)

Payer's viewpoint : Can RWD inform risk/benefit models for payers.
Shaun Rowark (NICE, UK)

Patients viewpoint
Robin Gage (Lakeland, FL, USA)

Statistical viewpoint
Graeme Hickey (Medtronic, USA)

Industry viewpoint.
Nancy Dreyer (Dreyer Strategies, USA)

Regulatory viewpoints
John Concato (FDA, USA), Claus Bolte (Ex-Swissmedic, Basel, CH)

The CVCT multi-stakeholder think tank moderated debate

RWD - WHAT IT IS, WHY IT'S USEFUL AND WHY CARDIOLOGISTS SHOULD CARE?
Chairpersons Robert Califf (FDA, USA) & Shirley Wang (Los Angeles, CA, USA)

Panelists : Ryan Ahern (Truveta, USA), Claus Bolte (Ex-Swissmedic, Basel, CH), Jawad H Butt (Copenhagen, DEN), Robert Califf (FDA, USA), Alison Cave (MHRA, UK), John Concato (FDA, USA), Issa Dahabreh (Boston, MA, USA), Nancy Dreyer (Dreyer Strategies, USA), Enrico Ferro (Boston, MA, USA), Robin Gage (Lakeland, FL, USA), Habib Gamra (Sousse, TN), Rich Gliklich (OM1, USA), Lars Hemkens (Basel, CH), Graeme Hickey (Medtronic, USA), Ramesh Nadarajah (Leeds, UK), Shaun Rowark (NICE, UK), Thomas Senderovitz (Novo Nordisk, DEN), Shirley Wang (Los Angeles, CA, USA), Ron Winslow (Ex Wall Street Journal, USA), Robert Yeh (Boston, MA, USA)

Room 1
Monday, December 9, 2024
11:00 -13:00

CVCT STATISTICS MASTERCLASS - 1
KEY TYPES OF TRIAL DESIGN.
HOW TO BEST MEET THE NEEDS OF KEY STAKEHOLDERS?
Chairpersons : Gregg Stone (New York, NY, USA) & Jan Tijssen (Amsterdam, NED)

Trial design requires both quality and creativity to achieve success. The aim of this MasterClass is to cover both current good practice and also strategic innovations to ensure that future trial designs best meet the challenges in advancing patient care. The speakers and discussants have a depth of experience in cardiovascular trials research and will relate the practical relevance of their insights to specific trial examples.

Pragmatic trials using patient health data: realities and myths.
Frank Rockhold (Durham, NC, USA)

Flexible trial designs: from frequentist multi-arm to bayesian platform trials.
Peter Juni (Oxford, UK)

Non-inferiority trials: when, why, how and choice of margin.
Stuart Pocock (London, UK)

The CVCT Multi-Stakeholder Think Tank Debate
WHICH TRIAL DESIGN TO MEET THE NEEDS OF KEY STAKEHOLDERS?
Chairpersons : Gregg Stone (New York, NY, USA) & Jan Tijssen (Amsterdam, NED)

Panelists : Issa Dahabreh (Boston, USA), Lars Hemkens (Basel, CH), Peter Juni (Oxford, UK), Stuart Pocock (London, UK), Frank Rockhold (Durham, NC, USA), Gregg Stone (New York, NY, USA), Jan Tijssen (Amsterdam, NED), Cindy Westerhout (Edmonton, CAN)

Room 1
Monday, December 9, 2024
14:00 -16:00

CVCT MASTERCLASS - 2
KEY ISSUES IN TRIAL PLANNING, DESIGN, SIZE AND ENDPOINTS
HOW TO BEST MEET THE NEEDS OF KEY STAKEHOLDERS?
Chairpersons : Peter Juni (Oxford, UK) & Stuart Pocock (London, UK)

Core challenges in trial design: patient enrichment, sham controls, choice of primary endpoint, including hierarchical composites.
Gregg Stone (New York, NY, USA)

Determining trial size, including sample size re-estimation.
Cindy Westerhout (Edmonton, CAN)

Testing primary and secondary endpoints with type i error control: how to best meet the needs of key stakeholders.
Lei Shen (Lilly, USA)

The CVCT Multi-Stakeholder Think Tank Debate
HOW STATISTICIANS MAY HELP MEET THE NEEDS OF KEY STAKEHOLDERS?
Chairpersons : Peter Juni (Oxford, UK) & Stuart Pocock (London, UK)

Panelists : Peter Juni (Oxford, UK), Stuart Pocock (London, UK), Frank Rockhold (Durham, NC, USA), Lei Shen (Lilly, USA), Gregg Stone (New York, NY, USA), Jan Tijssen (Amsterdam, NED), Cindy Westerhout (Edmonton, CAN)

Room 1
Monday, December 9, 2024
16:30 -19:00

WIN RATIO AND HIERARCHICAL ENDPOINT ANALYSES IN CLINICAL TRIALS
Chairpersons : Joao Ferreira (Porto, POR) & Stuart Pocock (London, UK)

Systematic review of published win ratio trials during 2022-24.
Stuart Pocock (London, UK)

Use and misuse of the win ratio: when is clinical meaning lost?
Norman Stockbridge (FDA, USA)

A clinical perspective on the win ratio.
Gregg Stone (New York, NY, USA)

Win ratio and the Cox model: are results different?
Joao Ferreira (Porto, POR)

Determining trial size with primary hierarchical endpoints.
Huiman Barnhart (Durham, NC, USA)

Statistical challenges in using the win ratio.
John Gregson (London, UK)

The CVCT Multi-Stakeholder Think Tank Debate

WIN RATIO: ARE WE TO THROW THE BABY WITH THE BATH WATER?
Chairpersons : Joao Ferreira (Porto, POR) & Stuart Pocock (London, UK)

Panelists : Huiman Barnhart (Durham, NC, USA), Issa Dahabreh (Boston, MA, USA), Efthymios Deliargyris (Cytosorbent, USA), Joao Ferreira (Porto, POR), John Gregson (London, UK), Stuart Pocock (London, UK), Norman Stockbridge (FDA, USA), Gregg Stone (New York, NY, USA), Cordula Zeller (Boehringer, GER)

Room 2
Monday, December 9, 2024
08:00 -10:30

NEUROCARDIOLOGY: RUNNING MULTIDISCIPLINARY TRIALS IN AN EMERGING SPECIALTY
Chairpersons : Rebecca Gottesman (NINDS, NIH, USA) & Edip Gurol (Boston, MA, USA)

What is neurocardiology? Ongoing trials relevant to neurocardiology.
Edip Gurol (Boston, MA, USA)

Cognition as an outcome measure in neurocardiology trials
Rebecca Gottesman (NINDS, NIH, USA)

Ischemic and hemorrhagic strokes: etiologies and their relevance to prevention.
Edip Gurol (Boston, MA, USA)

Extracranial large vessel disease: medical management vs surgery/stenting.
Seemant Chaturvedi (Baltimore, MA, USA)

Left atrial appendage closure for neurocardiology
Nassir Marrouche (Tulane, LA, USA)

Large simple trials for vascular surgeons - lessons learned from randomising over 6000 patients in ACST-1 and ACST-2.
Richard Bulbulia (Oxford, UK)

Challenges in enrolling stroke patients to secondary prevention trials: post-stroke cognitive and motor impairments.
Michelle Johansen (Baltimore, MA, USA)

Regulatory viewpoints.
Paul Lee (FDA,USA)

Patient's viewpoints
Juddson Rupp (Charlotte, NC, USA)
Hanneke Geelhoed (Harteraad, NED)

The CVCT Multi-Stakeholder Think Tank Debate
NEUROCARDIOLOGY TRIALS. HAVING THE BRAIN AT HEART.
Chairpersons : Rebecca Gottesman (NINDS, NIH, USA) & Edip Gurol (Boston, MA, USA)

Panelists : Richard Bulbulia (Oxford, UK), Seemant Chaturvedi (Baltimore, MA, USA), Hanneke Geelhoed (Harteraad, NED), Rebecca Gottesman (NINDS, NIH, USA), Edip Gurol (Boston, MA, USA), Michelle Johansen (Baltimore, MA, USA), Paul Lee (FDA,USA), Nassir Marrouche (Tulane, LA, USA), Juddson Rupp (Charlotte, NC, USA), Bertram Pitt (Ann Arbor, MI,USA), Faiez Zannad (Paris, FRA)

Room 2
Monday, December 9, 2024
11:00 -13:00

GENE THERAPY FOR GENETIC AND FOR COMMON HEART DISEASES PROGRESSING INTO CLINICAL STAGE

Chairpersons: Barry Greenberg (San Diego, CA, USA) & Silvia Priori (Pavia, ITA)

Mechanisms of in vivo gene editing using lipid nanoparticle delivery for cardiovascular disease.
Amit Khera (Verve Therapeutics, USA)

Targeting monogenetic disease.
Joseph Rossano (Philadelphia, PA, USA)

Design of clinical trials in the gene therapy time.
Silvia Priori (Pavia, ITA)

Targeting common heart diseases. Gene-PHIT in heart failure.
TBD

Targeting coronary artery disease and refractory angina: lessons learned from the EXACT clinical program for trial design
Eric Ducker (XyloCor, USA)

Early assessment for efficacy and de-risking strategies. Trial design and endpoints.
Seppo Ylä-Herttuala (Kuopio, FIN)

Once for all (or once-in-a-while) administration therapy. Implementation, adherence, and pricing consequences.
Shaun Rowark (NICE, UK), Abigail Wright (ICER, USA)

Regulatory viewpoint.
Erica Young (FDA, USA)

Patient's preference. Pill burden vs once for all (or once-in-a-while) administration therapy?
Alessia Argiro (Florence ITA)

Payer's viewpoint
TBD

The CVCT Multi-Stakeholder Think Tank Debate

GENE THERAPY FOR GENETIC AND FOR COMMON DISEASES PROGRESSING INTO CLINICAL STAGE

Chairpersons: Barry Greenberg (San Diego, CA, USA) & Silvia Priori (Pavia, ITA)

Panelists: Eric Adler (Lexeo Therapeutics, USA), Alessia Argiro (Florence ITA), Rossana Bongianino (Pavia, ITA), Eric Ducker (XyloCor, USA), Jason Duran (CRISPR Therapeutics), Al Gianchetti (Xylocor, USA), Barry Greenberg (San Diego, CA, USA), Amit Khera (Verve Therapeutics, USA), Marie Mide Michelsen (NovoNordisk, DEN), Chinwe Okoro (FDA, USA), Silvia Priori (Pavia, ITA), Joseph Rossano (Philadelphia, PA, USA), Jonathan Schwartz (RocketPharma, USA), Christine Seidman (Boston, MA, USA), Abigail Wright (ICER, USA), Seppo Ylä-Herttuala (Kuopio, FIN), Erica Young (FDA, USA)

Room 2
Monday, December 9, 2024
14:00 -16:00

CELL THERAPY TRIALS FOR HEART FAILURE.
RIGHT CELLS? RIGHT TARGET POPULATION? RIGHT DESIGN?
Chairpersons: Biykem Bozkurt (Houston, USA) & Philippe Ménasché (Paris, FRA)

What are the right cell products?

Stem cell derived products vs. Induced pleuripotent cell derived products.
Joshua Hare (Miami, FL, USA)

Exosomes and secretomes.
Philippe Ménasché (Paris, FRA)

Scaffolds, Cells, or Both? : Tissue Engineering for Cardiac Repair.
Karen Christman (San Diego, CA, USA)

What is the right target population?
Chronic HFpEF, post myocardial infarction or chronic HFpEF.
Emerson Perin (Houston, TX, USA)

What post-MI patients are still at high risk?
Tabassome Simon (Paris, FRA)

What are the right endpoints.
Scott Solomon (Boston, MA, USA)

What is the right design?
Population, study design and controls or alternatively matching treatment to disease.
Barry Greenberg (San Diego, CA, USA)

Industry viewpoint
Takehiko Kaneko (Heartseed, JPN)

Regulatory viewpoints
Erica Young (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate

CELL THERAPY TRIALS FOR HEART FAILURE.
RIGHT CELLS? RIGHT TARGET POPULATION? RIGHT DESIGN?
Chairpersons: Biykem Bozkurt (Houston, USA) & Philippe Ménasché (Paris, FRA)

Panelists : Biykem Bozkurt (Houston, USA), Karen Christman (San Diego, CA, USA), Kieran Docherty (Glasgow, UK), Matthieu de Kelbermatten (Cellprothera, FRA), Barry Greenberg (San Diego, CA, USA), Joshua Hare (Miami, FL, USA), Takehiko Kaneko (Heartseed, JPN), Philippe Ménasché (Paris, FRA), Emerson Perin (Houston, TX, USA), Lothar Roessig (AskBio-Bayer, GER), Tabassome Simon (Paris, FRA), Scott Solomon (Boston, MA, USA), Chinwe Okoro (FDA, USA), Erica Young (FDA, USA)

Room 2
Monday, December 9, 2024
16:30 -19:00

ARTIFICIAL INTELLIGENCE FOR TRIAL DESIGN, CONDUCT, ANALYSIS, & RESULT IMPLEMENTATION

Chairpersons: Jonathan Cunningham (Boston, MA, USA) & Harlan Krumholz (New Haven, USA)

The role of AI in large decentralized clinical trials.
Tor Biering-Sorenson (Copenhagen, DEN)

AI for clinical event adjudication.
Jonathan Cunningham (Boston, MA, USA)

What we need to realize AI's potential in clinical trials.
Sneha S Jain (Stanford, CA, USA)

AI for CV imaging core labs in trials.
Jose Rivero (Boston, MA, USA)

AI for dissemination & implementation of trial results.
Rohan Khera (JAMA, New Haven, CT, USA)

How should journals evaluate AI Tools & AI-generated results?
Harlan Krumholz (JACC, USA)

Statistical viewpoint.
Christopher Lindsell (Durham, NC, USA)

Industry viewpoints.
Lauren Bataille (Astrazeneca, USA)

Journal editor's viewpoint.
Stuart Spencer (Lancet, UK)
Jane Leopold (NEJM, Boston, USA)

Regulatory viewpoints.
Anindita Saha (FDA, USA)
Claus Bolte (Ex-Swissmedic, Basel, CH)

Patient's viewpoint
Caius Ovidiu Merșa (Timișoara, ROM)

The CVCT Multi-Stakeholder Think Tank Debate

ARTIFICIAL INTELLIGENCE FOR TRIAL DESIGN, CONDUCT, ANALYSIS, & RESULT IMPLEMENTATION

Chairpersons: Jonathan Cunningham (Boston, MA,USA) & Harlan Krumholz (New Haven, USA)

Panelists : Demilade Adedinsewo (Jacksonville, FL, USA), Tor Biering-Sorenson (Copenhagen, DEN), Lauren Bataille (Astrazeneca, USA), Claus Bolte (Ex-Swissmedic, Basel, CH), Jonathan Cunningham (Boston, MA,USA), Sneha Jain (Stanford, CA, USA), Rohan Khera (JAMA, New Haven, CT, USA),Harlan Krumholz (JACC, USA) , Jane Leopold (NEJM, Boston, USA), Christopher Lindsell (Durham, NC, USA), Caius Ovidiu Merșa (Timișoara, ROM),Jose Rivero (Boston, MA, USA), Anindita Saha (FDA, USA), Stuart Spencer (Lancet, UK), Ron Winslow (Ex Wall Street Journal, USA)

Room 3
Monday, December 9, 2024
08:00 -10:30

TRIALS IN WOMEN – WOMEN IN TRIALS: YES WE CAN!
CVCT-WomenAs1 joint session.
Chairpersons: Roxana Mehran (New York, NY, USA) & Tabassome Simon (Paris, FRA)

Regulatory tradewinds towards diversity.
Ariel Ash-Shakoor (FDA, USA)

The NHLBI's view on diversity in clinical trials.
Yves Rosenberg (NHLBI, NIH, USA)

The importance of Participation Prevalence Ratios (PPR)
Erin Bohula (Boston, MA, USA)

Enrollment caps: Yay or Nay?
Tabassome Simon (Paris, FRA)

Case study: CLEAR outcomes.
Leslie Cho (Cleveland, OH, USA)

Women as trial leaders: challenges and opportunities.
Harriette Van Spall (Hamilton, Canada)

Global viewpoint: how to incorporate sex/gender in CV clinial trial design.
Carolyn Lam (Singapore, SIN)

How to overcome the under-representation of women from the middle East and Africa in clinical trials?
Mirvat Alasnag (Jedda, KSA)

Learned societies viewpoint.
Mariell Jessup (Philadelphia, PA, USA)

Industry viewpoint
Manuela Negoita (Medtronic, USA)

Journal editor's viewpoint.
Flavia Geraldes (Lancet, UK)

The CVCT Multi-Stakeholder Think Tank Debate
TRIALS IN WOMEN – WOMEN IN TRIALS: YES WE CAN!
Chairpersons: Roxana Mehran (New York, NY, USA) & Tabassome Simon (Paris, FRA)

Panelists : Mirvat Alasnag (Jedda, KSA), Ariel Ash-Shakoor (FDA, USA), Sinjini Biswas (Melbourne, AUS), Erin Bohula (Boston, MA, USA), Leslie Cho (Cleveland, OH, USA), Flavia Geraldes (Lancet, UK), Mariell Jessup (Philadelphia, PA, USA), Carolyn Lam (Singapore, SIN), Roxana Mehran (New York, NY, USA), Manuela Negoita (Medtronic, USA), Yves Rosenberg (NHLBI, NIH, USA), Tabassome Simon (Paris, FRA), Harriette Van Spall (Hamilton, Canada)

Room 3
Monday, December 9, 2024
11:00 -13:00

THROMBOSIS TRIALS – NEW DRUGS – CHALLENGING INDICATIONS
Chairpersons: Renato Lopes (Durham, NC, USA) & Mpiko Ntsekhe (Cape Town, SA)

Prehospital anti-thrombotic therapy trials in STEMI.
Michael Gibson (Boston, MA, USA)

Industry viewpoints.
Robert Hillman (Celecor, USA), Sébastien Roux (Idorsia, CH)

Anticoagulation of valvular atrial fibrillation: is the debate over after the INVICTUS trial?
Mpiko Ntsekhe (Cape Town, SA)

Anticoagulation versus left atrial appendage closure post AF ablation: the OPTION trial.
Oussama M Wazni (Cleveland, OH, USA)

Management of the atrial fibrillation patient unsuitable for anticoagulant drugs
Michael Gibson (Boston, MA, USA)

Left atrial appendage closure for patients unsuitable for anticoagulant for atrial fibrillation: do we need a stronger level of recommendation in the guidelines?
Habib Gamra (Sousse, TN)

Role of anticoagulation in the management of the dialysis patient.
Renato Lopes (Durham, NC, USA)

The antiplatelet and thrombotic effects of SGLT1/2 vs SGLT2i
Bertram Pitt (Ann Arbor, USA)

The CVCT Multi-Stakeholder Think Tank Debate

THROMBOSIS TRIALS – NEW DRUGS – CHALLENGING INDICATIONS
Chairpersons: Renato Lopes (Durham, NC, USA) & Mpiko Ntsekhe (Cape Town, SA)

Panelists: Habib Gamra (Sousse, TN), Michael Gibson (Boston, MA, USA), Robert Hillman (Celecor, USA), Carolyn Lam (Singapore, SIN), Renato Lopes (Durham, NC, USA), Mpiko Ntsekhe (Cape Town, SA), Bertram Pitt (Ann Arbor, MI, USA), Sébastien Roux (Idorsia, CH), Oussama M Wazni (Cleveland, OH, USA)

Room 3
Monday, December 9, 2024
14:00 -16:00

ATRIAL FIBRILLATION (AF) BURDEN AND TRIAL ENDPOINT CONSIDERATIONS. HOW TO CONVINCE THE RESPECTIVE STAKEHOLDERS?

Chairpersons: Paulus Kirchhof (Hambourg, GER) & Andrea Russo (Cooper Health, USA)

How much atrial fibrillation (AF) is dangerous? The risks associated with persistent AF, paroxysmal AF and device-detected AF. What are the respective unmet needs in each group?
Thomas Deering (Atlanta, GA, USA)

Atrial Fibrillation burden in Africa and Middle East
Mohamed Sobhy (Alexandria, EGY)

Most recent evidence-based technical developments in atrial fibrillation ablation.
Josef Kautzner (Prague, CZ)

How to evaluate incremental technologies. Pre-and post-approval requirements.
Andrea Russo (Cooper Health, USA)

Efficacy endpoints: atrial fibrillation burden. How to measure and how clinically meaningful?
Jason Andrade (Vancouver, CAN)

Maximizing efficacy, safety & operational outcome/ technical convenience endpoint.
Nassir Marrouche (Tulane, LA, USA)

Consumer electronics.
Photoplethysmography-documented atrial fibrillation burden quantification?
Dominik Linz (Maastricht, NED)

Industry viewpoints.
Steven Lubitz (Novartis, USA)

Regulatory viewpoints.
Bindi Shah (FDA,USA)
TBD (EMA)

The CVCT Multi-Stakeholder Think Tank Debate

AF BURDEN AND OTHER TRIAL ENDPOINT CONSIDERATIONS. HOW TO CONVINCE THE RESPECTIVE STAKEHOLDERS?

Chairpersons : Paulus Kirchhof (Hambourg, GER) & Andrea Russo (Cooper Health, USA)

Panelists: Jason Andrade (Vancouver, CAN), Nikolaos Dagres (Berlin, GER), Thomas Deering (Atlanta, GA, USA), Josef Kautzner (Prague, CZ) , Paulus Kirchhof (Hambourg, GER), Jane Leopold (NEJM, Boston, USA), Dominik Linz (Maastricht, NED), Steven Lubitz (Novartis, USA), Nassir Marrouche (Tulane, LA, USA), Andrea Russo (Cooper Health, USA), Bindi Shah (FDA,USA), Mohamed Sobhy (Alexandria, EGY), Kenneth Stein (Boston Scientific, USA)

Room 3
Monday, December 9, 2024
16:30 -19:00

TRIALS AT THE HEART FAILURE/ELECTROPHYSIOLOGY INTERSECTION

Chairpersons : Thomas Deering (Atlanta, GA, USA) & Mariell Jessup (Philadelphia, PA, USA)

Conduction system pacing or CRT? What additional studies do we need?
HF specialist 's viewpoint.
Mariell Jessup (Philadelphia, PA, USA)

EP's viewpoint.
Paulus Kirchhof (Hambourg, GER)

Tempo matters: what heart rate is best in HF.
Markus Meyer (Minneapolis, MN, USA)

What role do CCM & barostim treatment options play – what trials are needed?
Daniel Burkhoff (New York, NY, USA)

New insights on ICD therapy in the midrange ejection fraction heart failure population
Valentina Kutyifa (Rochester, NY, USA)

Panel discussion
ICD therapy in HF: quick pitches building the case for a retrial

HF doc viewpoint. Do we have equipoise?
Javed Butler (Dallas, TX, USA)

EU-EP doc viewpoint. PROFID and CMR-ICD.
Gerd Hindricks (Leipzig, GER)

US-EP doc viewpoint. The CONTEMP-ICD trial.
Wojciech Zareba (Rochester, MN, USA)

Is it time to look at DNA in heart failure? Sudden death prediction using genetic information.
Silvia Priori (Pavia, ITA)

Timing matters: the value of extending time to decision for ICD implantation in patients with heart failure with reduced ejection fraction (HFrEF).
John Hummel (Columbus, OH, USA)

Industry viewpoints.
Zubin Eapen (Element Science, USA), Kenneth Stein (Boston Scientific, USA)

Regulatory viewpoint.
Brian Lewis (FDA, USA)

Patient's viewpoint.
Trudie Lobban (Heart Rhythm Alliance, London, UK)

The CVCT Multi-Stakeholder Think Tank Debate

WHAT PACING IN HEART FAILURE?
The HEART FAILURE – EP DEBATE

Chairpersons : Thomas Deering (Atlanta, GA, USA) & Mariell Jessup (Philadelphia, PA, USA)

Panelists: Daniel Burkhoff (New York, NY, USA), Javed Butler (Dallas, TX, USA), Nikolaos Dagres (Berlin, GER), Thomas Deering (Atlanta, GA, USA), Zubin Eapen (Element Science, USA), , Gerd Hindricks (Leipzig, GER), John Hummel (Columbus, OH, USA), Mariell Jessup (Philadelphia, PA, USA), Paulus Kirchhof (Hambourg, GER), Valentina Kutyifa (Rochester, NY, USA), Brian Lewis (FDA, USA), Trudie Lobban (Heart Rhythm Alliance, London, UK), Markus Meyer (Minneapolis, MN, USA), Silvia Priori (Pavia, ITA), Kenneth Stein (Boston Scientific, USA), Wojciech Zareba (Rochester, MN, USA)

Room 4
Monday, December 9, 2024
08:00 -10:30

REVIVAL OF HYPERTENSION TRIALS.
ONE-SIZE-FITS-ALL VS. PATIENT STRATIFICATION STRATEGIES
Chairpersons: Rhian Touyz (Montreal, CAN) & Bryan Williams (London, UK)

Emerging targeted therapies and the importance of patient stratification

Endothelin antagonists.
Michael Weber (New York, NY, USA)

RNA interference therapeutic agents.
Christopher Granger (Durham, NC, USA)

New biologic therapy for hypertension - activating the natriuretic peptide receptor.
Bryan Williams (London, UK)

Aldosterone dysregulation in hypertension and aldosterone targeted drugs.
Michel Azizi (Paris, FRA)

Targeting natriuresis to treat hypertension – back to the future
Bryan Williams (London, UK)

Beyond one-size-fits-all: how advanced patient phenotyping can revolutionize treatment approaches.
Christian Delles (Glagow, UK)

The virtues of one-size-fits-all anti-hypertensive polypill.
Antony Rodgers (Sydney, AUS)

Industry viewpoints.
Martine Clozel (Idorsia, CH), Jason Duran (CRISPR Therapeutics), Dion Zappe (Alnylam, USA)

Regulatory viewpoints.
Rekha Kambhampati (FDA, USA)

Lifestyle and implementation issues. The role of digital therapeutics.
Kazuomi Kario (Tochigi, JPN)

Hypertension in Africa : do we need more trials for a better control?
Anastase Dzudie (Douala, CM)

The CVCT Multi-Stakeholder Think Tank Debate
ANTIHYPERTENSIVE THERAPY
HOW NEW DRUGS NEW TRIALS AND NEW STRATEGIES MAY ADDRESS THE MANY UNMET NEEDS
Chairpersons: Rhian Touyz (Montreal, CAN) & Bryan Williams (London, UK)

Panelists: Michel Azizi (Paris, FRA), Martine Clozel (Idorsia, CH), Christian Delles (Glagow, UK), Jason Duran (CRISPR Therapeutics), Anastase Dzudie (Douala, CM), Christopher Granger (Durham, NC, USA), Rekha Kambhampati (FDA, USA), Kazuomi Kario (Tochigi, JPN), Marty Lefkowitz (Novartis, USA), Shira Perl (AstraZeneca, USA), Antony Rodgers (Sydney, AUS), Filip Surmont (AstraZeneca, SWE), Rhian Touyz (Montreal, CAN), Sotirios Tsimikas (Ionis, USA), Michael Weber (New York, NY, USA), Bryan Williams (London, UK) , Fred Yang (KBP BioScience, USA), Dion Zappe (Alnylam, UK)

Room 4
Monday, December 9, 2024
11:00 -13:00

DIABETES AND CKD THERAPIES
HOW TO IMPLEMENT THE FAST-GROWING EVIDENCE?
Chairpersons: Jennifer Green (Durham, NC, USA) & Peter Rossing (Copenhague, DEN)

The totality of available evidence

SGLT2i and GLP1RA
Hiddo Heerspink (Groningen, NED)

nsMRA
Peter Rossing (Copenhague, DEN)

Do we still need RASI in the mix
Matthew Weir (Baltimore, MA, USA)

Combining all of the above
Muthiah Vaduganathan, (Boston, MA, USA)

How to manage safety concerns as they should not harm implementation.
Brendon Neuen (Sydney, AUS)

How can we optimize implementation?
Guidelines, disease management programs and post approval studies.
Katherine Tuttle (Spokane, WA, USA)

Industry viewpoint.
Sibylle Hauske (Boehringer, GER)

Health economist / payer's viewpoints.
Borislava Mihaylova (London, UK)

Patient's viewpoint.
Nichole Jefferson (Dallas, TX, USA)

The CVCT Multi-Stakeholder Think Tank Debate
DIABETES AND CKD THERAPIES. HOW TO GET DIABETES AND CKD PATIENTS TO BENEFIT FROM THE EXPLOSION OF EVIDENE-BASED THERAPIES?
Chairpersons: Jennifer Green (Durham, NC, USA) & Peter Rossing (Copenhague, DEN)

Panelists: Maria Borentain (Bayer, GER), Kristine Buchholtz (NovoNordisk, DEN), Jennifer Green (Durham, NC, USA), Hiddo Heerspink (Groningen, NED), Sibylle Hauske (Boehringer, GER), Nichole Jefferson (Dallas, TX, USA), Dustin Little (AstraZeneca, USA) , Kaitlin Mayne (Oxford, UK), Borislava Mihaylova (London, UK), Brendon Neuen (Sydney, AUS), Peter Rossing (Copenhague, DEN), Katherine Tuttle (Spokane, WA, USA), Muthiah Vaduganathan, (Boston, MA, USA), Matthew Weir (Baltimore, MA, USA), Fred Yang (KBP BioScience, USA)

Room 4
Monday, December 9, 2024
14:00 -16:00

DIABETES AND CKM THERAPIES
GAPS IN EVIDENCE AND HOW TO ADDRESS.
NEW INVESTIGATIONAL DRUGS AND NEW TRIALS.
Chairpersons: Darren McGuire (Dallas, TX, USA) & Amy Mottl (Chapel Hill, NC, USA)

What additional/alternative agents are in the pipeline (NsMRA, Ziltivekimab, ASI, Cagrisema, dual/triple Incretins, etc...)?
Hiddo Heerspink (Groningen, NED)

What additional benefit should be investigated in future trials?
Darren McGuire (Dallas, TX, USA)

“An ounce of prevention...”. Evidence and trial opportunities in prediabetes.
Gregory Schwartz (Aurora, CO, USA)

What to do in Type 1 Diabetes?
Amy Mottl (Chapel Hill, NC, USA)

Industry viewpoint.
Sofia Gerward (NovoNordisk, DEN)

Regulatory viewpoint.
John Sharretts (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate

DIABETES AND CKM THERAPIES
ADDRESSING THE GAPS. NEW INVESTIGATIONAL DRUGS AND NEW TRIALS.
Chairpersons: Darren McGuire (Dallas, TX, USA) & Amy Mottl (Chapel Hill, NC, USA)

Panelists: Maria Borentain (Bayer, GER), Jyothis George (Amgen, USA), Sofia Gerward (NovoNordisk, DEN), Jennifer Green (Durham, NC, USA), Hiddo Heerspink (Groningen, NED), Nichole Jefferson (Dallas, TX, USA), Darren McGuire (Dallas, TX, USA), Amy Mottl (Chapel Hill, NC, USA), Fady T. Botros (Eli Lilly, USA), Peter Rossing (Copenhague, DEN), Gregory Schwartz (Aurora, CO, USA), John Sharretts (FDA, USA), Dominic Steubl (Boehringer, GER), Fred Yang (KBP BioScience, USA)

Room 4
Monday, December 9, 2024
16:30 -19:00

iCVCT
THROMBOSIS TRIALS. WHAT IS HAPPENING WITH FACTOR XI INHIBITORS?
Chairpersons: Michael Gibson (Boston, USA) & Vijay Kunadian (Newcastle upon Tyne, UK)

Overview of factor XI/XIa inhibitors as a biological target.
Jeffrey Weitz (Hamilton, CAN)

The results of OCEANIC-AF
Manesh Patel (Durham, NC, USA)

Update On Ongoing Adjacent AF Trials Targeting FXI/XIa.
LIBREXIA-AF / LILAC-TIMI-76
Carolyn Lam (Singapore, SIN)

Oral Factor XIa Inhibitor Trials in Secondary Stroke Prevention
OCEANIC-STROKE / LIBREXIA-STROKE
Mike Sharma (Hamilton, CAN)

Oral Factor XIa Inhibitor Trial After Recent ACS
LIBREXIA- ACS
Michael Gibson (Boston, USA)

Methodology perspective – Trial population and dose finding issues .
Edip Gurol (Boston, MA, USA)

Alternative dose finding options
Marc Bonaca (Denver, CO, USA)

DSMB perspective – Stopping trials prematurely.
David Cohen (Boston, USA)

Industry viewpoints.
Eva Muehlhofer (Bayer, GER), Nani Bhalla (BMS, USA)

Regulatory viewpoints.
Jordan Pomeroy (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate
THROMBOSIS TRIALS. DOES DOSE MATTER?
Chairpersons: Michael Gibson (Boston, USA) & Vijay Kunadian (Newcastle upon Tyne, UK)

Panelists: Nani Bhalla (BMS, USA), Marc Bonaca (Denver, CO, USA), Daniel Canos (FDA, USA), Habib Gamra (Sousse, TN), Michael Gibson (Boston, USA), Edip Gurol (Boston, MA, USA), Robert Hillman (Celecor, USA), Vijay Kunadian (Newcastle upon Tyne, UK), Carolyn Lam (Singapore, SIN), Renato Lopes (Durham, NC, USA), Manesh Patel (Durham, NC, USA), Eva Muehlhofer (Bayer, GER), Mpiko Ntsekhe (Cape Town, SA), Alexei Plotnikov (Janssen, CH), Jordan Pomeroy (FDA, USA), Sébastien Roux (Idorsia, CH), Mike Sharma (Hamilton, CAN), Jeffrey Weitz (Hamilton, CAN), So Young Kim (Bayer, GER)

Room 1
Tuesday, December 10, 2024
07:00 -08:00

RUNNING CLINICAL TRIALS AND DEVELOPING NOVEL THERAPIES IN ASIA PACIFIC
Chairpersons: Asita de Silva (Kelaniya, LK) & Lijing Yan (Kunshan, CHN)

Opening remarks
Lijing Yan (Kunshan, CHN)
Asita de Silva (Kelaniya, LK)

Conducting complex CVD trials in South Asia
Anubha Agarwal (St Louis, MI, USA)
Sophia Zoungas (Melbourne, AUS)

East-West similarities and differences in trial conduct and keys to successful collaboration
Christine Gouillard (USAI2, Singapore, SIN)
Carolyn Lam (Singapore, SIN)

Conducting high-impact traditional Chinese medicine cardiovascular trials
Xinli Li (Nanjing, CHN)
Steven Lok Fai Cheang (Nanjing, CHN)

The CVCT Multi-Stakeholder Think Tank Debate

RUNNING CLINICAL TRIALS AND DEVELOPING NOVEL THERAPIES IN ASIA PACIFIC
Chairpersons: Asita de Silva (Kelaniya, LK) & Lijing Yan (Kunshan, CHN)

Panelists: Anubha Agarwal (St Louis, MI, USA), Asita de Silva (Kelaniya, LK) , Liming Gan (Ribocure Pharmaceuticals, CHN), Christine Gouillard (USAI2, Singapore, SIN), Xiaodong Guan (Beijing, CHN), Yutaku Kaneta (PMDA, JPN), Kazuomi Kario (Tochigi, JPN), Carolyn Lam (Singapore, SIN), Xinli Li (Nanjing, CHN), Steven Lok Fai Cheang (Nanjing, CHN), Lijing Yan (Kunshan, CHN), Fred Yang (KBP BioScience, USA), Sophia Zoungas (Melbourne, AUS)

Room 1
Tuesday, December 10, 2024
08:00 -10:30

CVCT GOING GLOBAL. CLINICAL TRIALS IN APAC – LATAM – AFRICA/ME
Chairpersons: David Goff (NHLBI, NIH, USA) & Carolyn Lam (Singapore, SIN)

Need for global approach to Cardio-Renal-Metabolism clinical trials.
Faiez Zannad (Paris, FRA)

The Global Cardiovascular Research Funders Forum viewpoints. Transational funding of institutional trials (2x5 mins)
David Goff (NHLBI, NIH, USA)
Bryan Wiliams (British Heart Foundation, UK)

Traditional chinese medicine in Randomized Controlled Trials.
Xinli Li (Nanjing, CHN), Steven Lok Fai Cheang (Nanjing, CHN)

Drug development: local to global.
Liming Gan (Ribocure Pharmaceuticals, CHN)

ARO viewpoint.
Renato Lopes (Durham, NC, USA)

CRO viewpoint.
Chokri Jeribi (Eshmoun, TUN)

Ethnic differences in cardiovascular clinical trials.
Kazuomi Kario (Tochigi, JPN)

Investigator ‘s viewpoint.
Felipe Martinez (Cordoba, ARG)

Industry viewpoints.
Sangeetha Anand (CSL Vifor, SWI), Kenneth Stein (Boston Scientific, USA)

Regulatory viewpoints.
Agustina Bisio (ANMAT, ARG)
Manabu Minami (PMDA, JPN)

Journal editors’ viewpoints.
Harlan Krumholz (JACC, USA)

The CVCT Multi-Stakeholder Think Tank Debate
CLINICAL TRIALS IN APAC – LATAM – AFRICA/ME
What Would It Take for CV Clinical Trials to Go Global?
Chairpersons: David Goff (NHLBI, NIH, USA) & Carolyn Lam (Singapore, SIN)

Panelists : Anubha Agarwal (St Louis, MI, USA), Mirvat Alasnag (Saudi FDA, KSA), Sangeetha Anand (CSL Vifor, SWI), Kenneth Cavanaugh (FDA, USA), Steven Lok Fai Cheang (Nanjing, CHN), Chadli Dziri (Tunis, TUN), Asita de Silva (Kelaniya, LK), Habib Gamra (Sousse, TN), Liming Gan (Ribocure Pharmaceuticals, CHN), Jyothis George (Amgen, USA), David Goff (NHLBI, NIH, USA), Christine Gouillard (USAI2, Singapore, SIN), Chokri Jeribi (Eshmoun, TUN), Yutaku Kaneta (PMDA, JPN), Kazuomi Kario (Tochigi, JPN), Harlan Krumholz (JACC, USA), Carolyn Lam (Singapore, SIN) , Xinli Li (Nanjing, CHN), Renato Lopes (Durham, NC, USA), Christina Magnussen (Hamburg, GER), Felipe Martinez (Cordoba, ARG), Manabu Minami (PMDA, JPN), AUS), Azza Saleh (Cairo, EGY), Kenneth Stein (Boston Scientific, USA), Bryan Williams (British Heart Foundation, UK), Harriette Van Spall (Hamilton, ON, CAN), Ron Winslow (Ex Wall Street Journal, USA), Lijing Yan (Kunshan, CHN), Fred Yang (KBP BioScience, USA), Faiez Zannad (Paris, FRA), Sophia Zoungas (Melbourne, AUS)

Room 1
Tuesday, December 10, 2024
11:00 -13:00

PULMONARY ARTERIAL HYPERTENSION TRIALS. SHALL WE START THINKING OUT OF THE BOX? BACK FROM THE 7th WORLD PH SYMPOSIUM.

Chairpersons: Marc Humbert (Paris, FRA) & Vallerie McLaughlin (Ann Arbor, MI, USA)

Trial fortune and misfortune of emerging therapies for PAH.

Activin signaling inhibitors updates.
Marc Humbert (Paris, FRA)

Oral and inhaled tyrosine kinase inhibitors phase 2 and 3 RCT.
Olivier Sitbon (Paris, FRA)

Inhaled MK 5475. Insights from the INSIGNIA trial.
Guillermo Bortman (Buenos-Aires; ARG)

Synthetic external controls in PAH: Ready for prime time or yesterday's news
Steve Kawut (Philadelphia, PEN, USA)

Withdrawal trial designs in PAH.
Jason Weatherald (Edmonton, CA)

The value of patient preference and Patient-Reported Outcomes
Jimmy Ford (Chapel Hill, NC, USA)

Investigator's viewpoint.
Corey Ventetuolo (Providence, RI, USA)

Patient viewpoint.
Colleen Brunetti (Pulmonary Hypertension Association, USA)

Industry viewpoint.
Larry Zisman (Gossamer, USA)

FDA viewpoints.
Mitch Psotka (FDA, USA)

Payer's viewpoints.
Bart van der Schueren (EMA, BEL)

The CVCT Multi-Stakeholder Think Tank Debate

PULMONARY ARTERIAL HYPERTENSION INNOVATIVE DESIGNS

Chairpersons: Marc Humbert (Paris, FRA) & Vallerie McLaughlin (Ann Arbor, MI, USA)

Panelists : Guillermo Bortman (Buenos-Aires; ARG), Colleen Brunetti (Pulmonary Hypertension Association, USA), Bjorn Dahlof (Cereno, SWE), CQ Deng (United Therapeutics, USA), Jimmy Ford (Chapel Hill, NC, USA), Marc Humbert (Paris, FRA), Steve Kawut (Philadelphia, PEN, USA), Brad Maron (Baltimore, MA,USA), Vallerie McLaughlin (Ann Arbor, MI, USA), Mitch Psotka (FDA, USA), Sandeep Sahay (Houston, TX,USA), Olivier Sitbon (Paris, FRA), Bart van der Schueren (EMA, BEL), Corey Ventetuolo (Providence, RI, USA), Jason Weatherald (Edmonton, CA), Larry Zisman (Gossamer, USA)

Room 1
Tuesday, December 10, 2024
14:00 -16:00

GROUP 2 PULMONARY HYPERTENSION TRIALS. INTERSECTIONS WITH HEART FAILURE
Chairpersons: Mardi Gomberg-Maitland (Washington, DC, USA) & Milton Packer (Dallas, TX, USA)

Epidemiology and unmet needs in Group 2 PH.
Brad Maron (Baltimore, MD, USA)

The prevalence of PH in HFpEF patients
Mardi Gomberg-Maitland (Washington, DC, USA)

A critical analysis of currently available RCTs in Group 2 PH.
Jean-Luc Vachiéry (Brussels, BEL)

Sotatercept for Group 2 PH: CADENCE trial update.
Mardi Gomberg-Maitland (Washington, DC, USA)

Levosimendan for Group 2 PH: From HELP to the LEVEL trials.
Sanjiv Shah (Chicago, IL, USA)

A heart failure trialist critical appraisal of contemporary PAH trials.
Milton Packer (Dallas, TX, USA)

Industry viewpoint.
Alessia Urbinati (Merck, USA)

Regulatory viewpoints.
Mitch Psotka (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate

GROUP 2 PULMONARY HYPERTENSION TRIALS. INTERSECTIONS WITH HEART FAILURE
Chairpersons: Mardi Gomberg-Maitland (Washington, DC, USA) & Milton Packer (Dallas, TX, USA)

Panelists : Daniel Burkhoff (New York, NY, USA), Chris Giordano (Tenax Therapeutics, USA), Mardi Gomberg-Maitland (Washington, DC, USA), Brad Maron (Baltimore, MD, USA), Milton Packer (Dallas, TX, USA), Mitch Psotka (FDA, USA), Sanjiv Shah (Chicago, IL, USA), Alessia Urbinati (Merck, USA), Jean-Luc Vachiéry (Brussels, BEL)

Room 1
Tuesday, December 10, 2024
16:30 -18:30

GROUP 3 PULMONARY HYPERTENSION TRIALS. INTERSECTIONS WITH RESPIRATORY DISEASES
Chairpersons: Kelly Chin (Dallas, TX, USA) & Gérald Simonneau (Paris, FRA)

Interstitial Lung Disease – PH.

A critical analysis of PDE5i RCTs for ILD-PH.
Steve Kawut (Philadelphia, PEN, USA)

Inhaled Treprostinil for ILD-PH.
Oksana Shlobin (Washington, DC, USA)

Novel therapies for ILD-PH.
Rajan Saggar (UCLA, CA, USA)

Chronic Obstructive Pulmonary Hypertension

Inhaled Treprostinil for COPD-PH: PERFECT trial.
Steven Nathan (Washington, DC, USA)

Inhaled MK-5475 for COPD-PH.
Paul Hassoun (Baltimore, MA, USA)

Tadalafil for COPD-PH: ERASE PH-COPD trial update.
Marc Humbert (Paris, FRA)

Investigator's viewpoint.
Sandeep Sahay (Houston, TX, USA)

Industry viewpoints.
Mackenzie Ford (Merck, USA)

FDA/EMA viewpoint.
Mitch Psotka (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate

GROUP 3 PULMONARY HYPERTENSION TRIALS. INTERSECTIONS WITH RESPIRATORY DISEASES
Chairpersons: Kelly Chin (Dallas, TX, USA) & Gérald Simonneau (Paris, FRA)

Panelists : Kelly Chin (Dallas, TX, USA), Bjorn Dahlof (Cereno, SWE), Mackenzie Ford (Merck, USA), Paul Hassoun (Baltimore, MA, USA), Marc Humbert (Paris, FRA), Steve Kawut (Philadelphia, PEN, USA), Brad Maron (Baltimore, MA, USA), Oksana Shlobin (Washington, DC, USA), Mitch Psotka (FDA, USA), Rajan Saggar (UCLA, CA, USA), Sandeep Sahay (Houston, TX, USA), Carlos Sanmarco (Roivant, USA), Oksana Shlobin (Washington, DC, USA), Gérald Simonneau (Paris, FRA), Corey Ventetuolo (Providence, RI, USA)

Tuesday, December 10, 2024
18:30 - 19:00

PLENARY KEYNOTE LECTURE
by HYLTON JOFFE
FDA, Director Office of Cardiology, Hematology, Endocrinology and Nephrology

Tuesday, December 10, 2024

19:00 - 21:00

ATTENDED POSTER VISIT
WINE AND CHEESE SESSION

Room 2
Tuesday, December 10, 2024
07:00 -08:00

RUNNING CLINICAL TRIALS AND DEVELOPING NOVEL THERAPIES IN AFRICA-MIDDLE EAST
Chairpersons: Habib Gamra (Monastir, TUN) & Mirvat Alasnag (Saudi FDA, KSA)

Opening remarks
Mirvat Alasnag (Jeddah, KSA)
Habib Gamra (Monastir, TUN)

How much clinical research is being performed in Africa and Middle East
Mohamed Sobhy (Alexandria, EGY)

Priorities for health research in Africa and Middle East
Ntobeko Ntusi (Cape Town, ZAF)

Upgrading and harmonizing the regulatory environment in Africa and Middle East
Faiez Zannad (Paris, FRA)

The CRO experience in conducting clinical trials in the Africa and Middle East
Chokri Jeribi (Eshmoun, TUN)

The CVCT Multi-Stakeholder Think Tank Debate

RUNNING CLINICAL TRIALS AND DEVELOPING NOVEL THERAPIES IN AFRICA- MIDDLE EAST
Chairpersons: Habib Gamra (Monastir, TUN) & Mirvat Alasnag (Saudi FDA, KSA)

Panelists : Mirvat Alasnag (Jeddah, KSA), Chadli Dziri (Tunis, TUN) , Habib Gamra (Monastir, TUN), Chokri Jeribi (Eshmoun, TUN), Ntobeko Ntusi (Cape Town, ZAF), Mohamed Sobhy (Alexandria, EGY)

Room 2
Tuesday, December 10, 2024
08:00 -10:30

GLP1 RA FOR CARDIO-KIDNEY-METABOLISM
DISSECTING THE INCREMENTAL EVIDENCE
Chairpersons: Joao Ferreira (Porto, POR) & Katherine Tuttle (Spokane, WA, USA)

FLOW trial main results.
Peter Rossing (Copenhague, DEN)

Mechanistic insight and plausibility. Do we know how GLP1RA work?
Katherine Tuttle (Spokane, WA, USA)

Safety of GLP1RAs. Results from trials and from Real World.
Marc Petrie (Glasgow, UK)

What do GLP1RAs add to other CKM therapies.
Brendon Neuen (Sydney, AUS)

Heart failure patients and heart failure outcomes in GLP1RA trials.
Joao Ferreira (Porto, POR)

Statistical viewpoint. Stopping early and other considerations.
Jan Tijssen (Amsterdam, NED)

Moving toward a 4-Pillar therapy? Issues relative to combination therapy.
Meg Jardine (Sydney, AUS)

Industry viewpoints.
Dorthe Charlotte Skovgaard (Novonordisk, DEN), Bettina Kraus (Boehringer, GER), TBD (Lilly, USA)

Regulatory viewpoints.
Rekha Kambhampati (FDA, USA)

Patient's viewpoint.
Steve Macari (Poitiers, FRA)

The CVCT Multi-Stakeholder Think Tank Debate
GLP1 RA FOR CARDIO-KIDNEY-METABOLISM
RESULTS AND PRACTICAL CONSEQUENCES OF ACCUMULATING EVIDENCE.
Chairpersons: Joao Ferreira (Porto, POR) & Katherine Tuttle (Spokane, WA, USA)

Panelists : Joao Ferreira (Porto, POR), Meg Jardine (Sydney, AUS), Rekha Kambhampati (FDA, USA), Bettina Kraus (Boehringer, GER), Agnes Koczo (Pittsburgh, PA, USA), Steve Macari (Poitiers, FRA), Brendon Neuen (Sydney, AUS), Marc Petrie (Glasgow, UK), Peter Rossing (Copenhague, DEN), Abdullah Shehab (Al Ain, UAE), Dorthe Charlotte Skovgaard (NovoNordisk, DEN), Jan Tijssen (Amsterdam, NED), Katherine Tuttle (Spokane, WA, USA)

Room 2
Tuesday, December 10, 2024
11:00 -13:00

PEDIATRIC CARDIOLOGY SPECIFIC CLINICAL TRIAL CONSIDERATIONS
Chairpersons: Shelley Miyamoto (Denver, CO, USA) & Gail Pearson (NHLBI, USA)

What makes pediatric trials different?
Joseph Rossano (Philadelphia, PA, USA)

Children are not small adults! Rationale for pediatric drug development.
Jennifer Li (Durham, NC, USA)

Why bother labeling drugs/devices for children?
George Van Hare (FDA, USA)

Moving from adult to pediatric therapies in HF: VICTORIA & VALOR trials.
Mackenzie Ford (Merck, USA)

What are ideal drug candidates for study?
Donato Bonifazi (Pavia, ITA)

What endpoints are valid ?

Use of biomarkers in pediatric clinical trials.
Shelley Miyamoto (Denver, CO, USA)

Role of Patient Reported Outcomes. The PCORI CHI RON study.
Anitha John (Washington DC, USA)

Regulatory viewpoints.
Ann Punnoose (FDA, USA)
Chinwe Okoro (FDA, USA)
Claus Bolte (Ex-Swissmedic, Basel, CH)

Who funds clinical trials? Funders viewpoints (5 mins each).

NHLBI
Gail Pearson (NHLBI, USA)

Role of Foundations
Kirstie Keller (Additional Ventures, USA)

The CVCT Multi-Stakeholder Think Tank Debate
PEDIATRIC SPECIFIC CLINICAL TRIAL CONSIDERATIONS
Chairpersons: Shelley Miyamoto (Denver, CO, USA) & Gail Pearson (NHLBI, USA)

Panelists : Claus Bolte (Ex-Swissmedic, Basel, CH), Donato Bonifazi (Pavia, ITA), Mackenzie Ford (Merck, USA), Anitha John (Washington DC, USA), Kirstie Keller (Additional Ventures, USA),Jennifer Li (Durham, NC, USA), Shelley Miyamoto (Denver, CO, USA), Gail Pearson (NHLBI, USA), Chinwe Okoro (FDA, USA)Ann Punnoose (FDA, USA), Joseph Rossano (Philadelphia, PA, USA)

Room 2
Tuesday, December 10, 2024
14:00 -16:00

GETTING A PEDIATRIC CARDIOLOGY DEVICE TO TRIAL
Chairpersons : Angela Lorts (Cincinnati, OH, USA) & Elfriede Pahl (Wilmette, IL, USA)

Experience with preclinical work on devices for children.
Beverly Tang (Starlight Cardiovascular, USA)

New devices for supporting infants/children.
Takeshi Shinkawa (Tokyo, JPN)

Pediatric EP devices, why class III (CV) devices won't get through a pediatric device consortium.
Anne Dubin (Palo Alto, CA, USA)

Highlights of the PICCOLO PDA device - for preemies and PIVOTAL trial.
Thomas Forbes (Hollywood, FL, USA)

The European perspective on devices/VADs. What devices are preferred for MCS in children in 2024?
Daniel Zimpfer (Vienna, AUT)

Artificial Intelligence/Machine Learning and the use of digital twinning.
Alison Marsden (Stanford, CA, USA).

Real World Data and Registries– How do they inform clinical trials?

ACTION Registry & lessons learned from Berlin trial.
Angela Lorts (Cincinatti, OH, USA)

PHTS lessons learned.
Kevin Daly (Boston, MA, USA)

The stress trial. How to leverage existing resources from Society of Thoracic Surgery Registry.
Kevin Hill (Durham, NC, USA)

Industry viewpoint
Richard Dujmovic (Boston Scientific, USA)

FDA's perspectives on using of real world data in regulatory decision making
George Van Hare (FDA, USA)

EU perspectives on using of real world data in regulatory decision making
Donato Bonifazi (EMA, ITA)

The CVCT Multi-Stakeholder Think Tank Debate

GETTING A PEDIATRIC CARDIOLOGY DEVICE TO TRIAL
Chairpersons : Angela Lorts (Cincinnati, OH, USA) & Elfriede Pahl (Wilmette, IL, USA)

Panelists : Donato Bonifazi (EMA, ITA), Kevin Daly (Boston, MA, USA), Anne Dubin (Palo Alto, CA, USA), , Richard Dujmovic (Boston Scientific, USA), Thomas Forbes (Hollywood, FL, USA), Kevin Hill (Durham, NC, USA), Kirstie Keller (Additional Ventures, USA), Elfriede Pahl (Wilmette, IL, USA), Takeshi Shinkawa (Tokyo, JPN), Beverly Tang (Starlight Cardiovascular, USA), George Van Hare (FDA, USA), Daniel Zimpfer (Vienna, AUT)

Room 2
Tuesday, December 10, 2024
16:30 -18:30

BIOLOGICS THERAPEUTICS MOVING TO CLINICAL STAGE
Chairpersons: Marianna Fontana (London, UK) & Thomas Thum (Hannover, GER)

Overview of novel and ongoing clinical trials.

siRNA and AntiSense Oligonucleotides therapeutics.TBD
Konstantinos Stellos (Francfort, GER)

miRNA therapeutics.
Thomas Thum (Cardior, GER)

Antibody therapies .
Marianna Fontana (London, UK)

Seeking cardiovascular indications.
Mads Engelmann (Novo Nordisk, DEN)

Targeting Inherited Arrhythmias with Molecular Genetic Therapies
Gabriel Brooks (Solid Biosenses, USA)

Seeking kidney indications.
Christoph Wanner (Wursburg, GER)

Industry viewpoints.
Anna Borodovsky (Alnylam, USA), Lothar Roessig (Askbio/Bayer, GER), Ricardo Rocha (Intellia Therapeutics, USA), Bryan Young (Regeneron, USA), Chris O'Donnell (Novartis, USA)

Journal editor's viewpoint.
Jane Leopold (NEJM, Boston, USA)

Regulatory viewpoints.
TBD (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate

BIOLOGICS THERAPEUTICS MOVING TO CLINICAL STAGE
Chairpersons: Marianna Fontana (London, UK) & Thomas Thum (Hannover, GER)

Panelists: Gabriel Brooks (Solid Biosenses, USA), Mads Engelmann (Novo Nordisk, DEN), Marianna Fontana (London, UK), Anna Borodovsky (Alnylam, USA), Jane Leopold (NEJM, Boston, USA), Chris O'Donnell (Novartis, USA), Lothar Roessig (Askbio/Bayer, GER), Ricardo Rocha (Intellia Therapeutics, USA), Konstantinos Stellos (Francfort, GER), Thomas Thum (Cardior, GER), Christoph Wanner (Wursburg, GER), Bryan Young (Regeneron, USA), Dion Zappe (Alnylam, UK)

Room 3
Tuesday, December 10, 2024
07:00 -08:00

RUNNING CLINICAL TRIALS AND DEVELOPING NOVEL THERAPIES IN LATAM
Chairpersons: Renato Lopes (Durham, NC, USA) & Felipe Martinez (Cordoba, ARG)

Opening remarks
Renato Lopes (Durham, NC, USA)
Felipe Martinez (Cordoba, ARG)

How much clinical research is being performed in LATAM
André Zimmerman (Porto Alegre, BRA)

Priorities for health research in LATAM
Clara Saldarriaga (Medellin, COL)

The CRO/ARO experience in conducting clinical trials in the Africa and Middle East
Renato Lopes (Durham, NC, USA)

The CVCT Multi-Stakeholder Think Tank Debate

INVOLVING LATAM IN THE GLOBAL TRIALS ENTERPRISE
Chairpersons: Renato Lopes (Durham, NC, USA) & Felipe Martinez (Cordoba, ARG)

Panelists : Anastase Dzudie (Douala, CM), Renato Lopes (Durham, NC, USA), Felipe Martinez (Cordoba, ARG), Clara Saldarriaga (Medelin, COL), André Zimmerman (Porto Alegre, BRA)

Room 3
Tuesday, December 10, 2024
08:00 -10:30

SAFETY EVALUATION OF CARDIOVASCULAR DRUGS AND DEVICES
Chairpersons: Bertram Pitt (Ann Arbor, USA) & Nawab Qizilbash (Madrid, ESP)

The proper assessment of drug safety is a key requirement of successful drug and device development and consequent use. This session will bring leading experts in the field to present and debate what are the key issues in safety evaluation of both pre-licensing trials and post-approval studies.The combination of clinical, statistical, epidemiological, industry, regulatory and HTA perspectives should ensure a lively interactive session.

Part 1 EVALUATION OF SAFETY IN PIVOTAL PHASE 3 TRIALS (PRE-LICENSING)

Clinical perspective.
Christopher Granger (Durham, NC, USA)

Data Safety Monitoring Boards.
Barry Greenberg (San Diego, CA, USA)

Statistical perspective.
John Gregson (London, UK)

Industry perspective.
Anastasia Lesogor (Novartis, USA)

Regulatory perspective.
Mary Ross Southworth (FDA, USA)

Patient's viewpoint.
Penilla Gunther (Stockholm, SWE)

The CVCT Multi-Stakeholder Think Tank Debate
Part 1: HOW TO PROGRESS EVALUATION IN PRE-APPROVAL TRIALS?
Chairpersons: Bertram Pitt (Ann Arbor, USA) & Nawab Qizilbash (Madrid, ESP)

Panelists : Richard Dujmovic (Boston Scientific, USA), Joann Evangelista (Genentech, USA), Christopher Granger (Durham, NC, USA), Barry Greenberg (San Diego, CA, USA), John Gregson (London, UK), Penilla Gunther (Stockholm, SWE) , Anastasia Lesogor (Novartis, USA), Bertram Pitt (Ann Arbor, USA), Nawab Qizilbash (Madrid, ESP), Frank Rockhold (Durham, NC, USA), Mary Ross Southworth (FDA, USA), Bram Zuckerman (FDA, USA)

Room 3
Tuesday, December 10, 2024
08:00 -10:30

SAFETY EVALUATION OF CARDIOVASCULAR DRUGS AND DEVICES
Chairpersons: Bertram Pitt (Ann Arbor, USA) & Nawab Qizilbash (Madrid, ESP)

Part 2: EVALUATION OF SAFETY POST-APPROVAL

Epidemiological/CRO perspective.
Nawab Qizilbash (Madrid, ESP)

Methodological perspective.
Frank Rockhold (Durham, NC, USA)

Industry perspective.
Richard Dujmovic (Boston Scientific, USA), Anastasia Lesogor (Novartis, USA)

Regulatory perspective.
Bart van der Schueren (EMA, BEL)
Bram Zuckerman (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate
Part 2: EVALUATION OF SAFETY POST-APPROVAL
Chairpersons: Bertram Pitt (Ann Arbor, USA) & Nawab Qizilbash (Madrid, ESP)

Panelists : Richard Dujmovic (Boston Scientific, USA) John Gregson (London, UK), Anastasia Lesogor (Novartis, USA), Bertram Pitt (Ann Arbor, USA), Nawab Qizilbash (Madrid, ESP), Frank Rockhold (Durham, NC, USA), Norman Stockbridge (FDA, USA), Bart van der Schueren (EMA, BEL), Bram Zuckerman (FDA, USA)

Room 3
Tuesday, December 10, 2024
11:00 -13:00

THE FUTURE OF POST-MI DRUG THERAPY TRIALS
Chairpersons: Josephine Harrington (Durham, NC, USA) & Sanjit Jolly (Hamilton, CAN)

Trials in patients developing heart failure post-myocardial infarction

Main results of EMPACT MI.
Javed Butler (Dallas, TX, USA)

Statistical viewpoint. EMPACT MI and AEGIS II.
Stuart Pocock (London, UK)

Colchicine and Spironolactone in unselected post-MI population. CLEAR-SYNERGY main results, and meta-analysis.
Sanjit Jolly (Hamilton, CAN)

Mitigating the challenge of declining event rate. The value of win ratio and of ranking/ordinal endpoint in post-MI trials.
John Gregson (London, UK)

Putting the results of recent post-MI patients in the context of clinical practice.
Mariell Jessup (Philadelphia, Pa, USA)

The declining residual risk in post-MI patients. What future post-MI trial design should look like.
Robert Mentz (Durham, NC, USA)

Industry viewpoints
Sébastien Roux (Idorsia, CH), Mikhail Sumin (Boehringer, GER), Thomas Thum (Cardior, GER)

Regulatory viewpoint.
Charu Gandotra (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate
THE FUTURE OF POST-MI TRIALS POST EMPACT-MI
Chairpersons: Josephine Harrington (Durham, NC, USA), Sanjit Jolly (Hamilton, CAN)

Panelists: Javed Butler (Dallas, TX, USA), Charu Gandotra (FDA, USA), John Gregson (London, UK), Josephine Harrington (Durham, NC, USA), Mariell Jessup (Philadelphia, PA, USA), Sanjit Jolly (Hamilton, CAN), Robert Mentz (Durham, NC, USA), Stuart Pocock (London, UK), Xavier Rosselló (Madrid, ESP), Sébastien Roux (Idorsia, CH), Mikhail Sumin (Boehringer, GER), Thomas Thum (Cardior, GER)

Room 3
Tuesday, December 10, 2024
14:00 -16:00

CORONARY CT ATHEROSCLEROSIS AS A PROGNOSTIC AND SURROGATE BIOMARKER IN CLINICAL TRIALS

Chairpersons: Kelley Branch (Seattle, WA, USA) & Pamela Douglas (Durham, NC, USA)

CAD imaging endpoints to accelerate drug development and translation.
Cheerag Shirodaria (Oxford, UK)

Which coronary atherosclerosis imaging test(s) and metrics should be used as an enrichment biomarker to improve efficiency of CAD clinical trials?
Ron Blankstein (Boston, MA, USA)

Pragmatic considerations for CTCA, CAD and NCPV measures for enrichment in clinical trials.
Leslee Shaw (New York, NY, USA)

Coronary atherosclerosis CT imaging as a surrogate endpoint to accelerate CAD drug development.
Pamela Douglas (Durham, NC, USA)

Future Trialist viewpoint
Guiomar Mendieta (Madrid, ESP)

Industry viewpoints.
Craig Basson (Bitterrootbio, USA), Denise Yates (Novartis, USA)

Regulatory viewpoints.
Jeff Siegel (FDA, USA)
Norman Stockbridge (FDA, USA)

Patient's viewpoint.
Philip Collis (British Heart Foundation, UK)

The CVCT Multi-Stakeholder Think Tank Debate

CAN OR WHEN COULD CT PLAQUE IMAGING REPLACE ADVERSE EVENTS ASSESSMENTS IN CLINICAL TRIALS

Chairpersons: Kelley Branch (Seattle, WA, USA) & Pamela Douglas (Durham, NC, USA)

Panelists: Craig Basson (BitterrootBio, USA), Ron Blankstein (Boston, MA, USA), Kelley Branch (Seattle, WA, USA), Daniel Canos (FDA, USA), Philip Collis (British Heart Foundation, UK), Pamela Douglas (Durham, NC, USA), Richard George (Regeneron, USA), Guiomar Mendieta (Madrid, ESP), Leslee Shaw (New York, NY, USA), Abdullah Shehab (Al Ain, UAE)Cheerag Shirodaria (Oxford, UK), Jeff Siegel (FDA, USA), Norm Stockbridge (FDA, USA), Denise Yates (Novartis, USA)

Room 3
Tuesday, December 10, 2024
16:30 -18:30

CVCT-NHLBI joint session
A SPOTLIGHT ON GLOBAL IMPLEMENTATION TRIALS
Chairpersons : George Mensah (NHLBI,USA) & Yves Rosenberg (NHLBI, NIH, USA)

Introduction: how trialists may ultimately increase the reach of their intervention by prospectively designing and simultaneously testing for effectiveness and implementation.
George Mensah (NHLBI,USA)

Effectiveness-Implementation Hybrid Study Approaches
Harriette Van Spall (Hamilton, ON, CAN)

Case study: learning about clinical and implementation outcomes simultaneously.
Margrét Leósdóttir (Malmö, SWE)

Translating clinical trials to practice: implementing a national program to increase influenza vaccinations
Tor Biering-Sorensen (Copenhague, DEN)

How to build implementation research plans into phase 3 trials.
Harriette Van Spall (Hamilton, ON, CAN)

Implementation trials in Asia.
Lijing Yan (Kunshan, CHN)

Editor's viewpoints
Michael Basson (Nature Medicine, USA)
Chloe Wilson (Lancet, UK)

The CVCT Multi-Stakeholder Think Tank Debate

CVCT-NHLBI joint session
DESIGNING TRIALS WITH IMPLEMENTATION IN MIND
Chairpersons : George Mensah (NHLBI,USA) & Yves Rosenberg (NHLBI, NIH, USA)

Panelists: Michael Basson (Nature Medicine, USA), Tor Biering-Sorensen (Copenhague, DEN), Jesper Jensen (Copenhague, DEN), Margrét Leósdóttir (Malmö, SWE), George Mensah (NHLBI,USA), Yves Rosenberg (NHLBI, NIH, USA), Harriette Van Spall (Hamilton, ON, CAN), Chloe Wilson (Lancet, UK), Lijing Yan (Kunshan, CHN)

Room 4
Tuesday, December 10, 2024
08:00 -10:30

CARDIAC AMYLOIDOSIS.
HOW LATEST PROGRESS IN DETECTION, TREATMENT AND PREVENTION MAY AFFECT FUTURE TRIAL DESIGN.
Chairpersons: Marianna Fontana (London, UK) & Dan Judge (Charleston, SC, USA)

Gene-silencing, antibody therapy and new kids in the block: progress in ATTR stabilization and ATTR prevention drug therapy.
Alberto Aimo (Pisa, ITA)

Lessons from science, biology, clinical medicine and clinical trials. The future of amyloidosis as a rare disease and consequences on new cardiac amyloidosis trials.
Ahmad Masri (Portland, OR, USA)

Progress in cardiac amyloidosis diagnosis and AI tracking of cardiac amyloidosis
High-throughput identification of ATTR-CM at scale.
Rohan Khera (New Haven, CT, USA)
Shahzeb Khan (Chicago, IL, USA)

Most recent clinical trials results and approvals.
Marianna Fontana (London, UK)

What should be the right background and control therapy in future amyloidosis trials?
Shahzeb Khan (Chicago, IL, USA)

How to define disease progression endpoints in prevention trials? Surrogates vs. symptoms vs. outcomes.
Dan Judge (Charleston, SC, USA)

Industry viewpoints.
Sameer Bansilal (Alnylam, USA), Adam Castano (BridgeBio, USA), Christie Nie (Prothena, USA), SotiriosTsimikas (Ionis,USA)

Patient ‘s viewpoint.
Isabelle Lousada (Amyloidosis Research Consortium, USA)

Regulatory viewpoint.
Rosalyn Adigun (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate

CARDIAC AMYLOIDOSIS.
SHAPING THE NEXT WAVE OF CLINICAL TRIALS.
Chairpersons: Marianna Fontana (London, UK) & Dan Judge (Charleston, SC, USA)

Panelists : Rosalyn Adigun (FDA, USA), Alberto Aimo (Pisa,ITA), Sameer Bansilal (Alnylam, USA), Adam Castano (BridgeBio, USA), Marianna Fontana (London, UK), Dan Judge (Charleston, SC, USA), Shahzeb Khan (Chicago, IL, USA), Peter Kahr (Neurimmune, CH), Shahzeb Khan (Chicago, IL, USA), Rohan Khera (New Haven, CT, USA), Isabelle Lousada (Amyloidosis Research Consortium, USA), Ahmad Masri (Portland, OR, USA), Christie Nie (Prothena, USA), Sotirios Tsimikas (Ionis,USA)), Liron Walsh (Intellia Therapeutics, USA)

Room 4
Tuesday, December 10, 2024
11:00 -13:00

HYPERTROPHIC CARDIOMYOPATHIES (HCM). Part 1
PROGRESS IN DETECTION AND CLINICAL MANAGEMENT LIKELY TO AFFECT FUTURE TRIALS
Chairpersons: Kimberly Hong (San Diego, CA, USA) & Martin Maron (Boston, MA, USA)

Most recent HCM clinical trials results and approvals.
Martin Maron (Boston, MA, USA)

Expected implementation of recent trials findings.

Updating the guidelines.
Elena Arbelo (Barcelona, ESP)

How recent findings may translate into daily practice.
Masataka Kawana (Stanford, CA, USA)

The genetic/pediatric perspective.
Kimberly Hong (San Diego, CA, USA)

The consequences of the changing landscape on future HCM trials.

Patient identification for clinical trials progress in HCM diagnosis, genomics and imaging.
James Moon (MyCardium AI Ltd, UK)

How Ai may help understanding Early stage HCM
Maxime Touzot (Owkin, FRA)

Industry viewpoint.
Steve Heitner (Cytokinetics, USA)

Patient's viewpoint.
Lisa Salberg (HCMA, USA)

The CVCT Multi-Stakeholder Think Tank Debate
HYPERTROPHIC CARDIOMYOPATHIES. Part 1
HOW PROGRESS IN DISEASE DETECTION AND MANAGEMENT WILL AFFECT PATIENT SELECTION IN FUTURE TRIALS
Chairpersons: Kimberly Hong (San Diego, CA, USA) & Martin Maron (Boston, MA, USA)

Panelists: Eric Adler (Lexeo, USA), Elena Arbelo (Barcelona, ESP), Arnaud Bastien (BMS, USA), Steve Heitner (Cytokinetics, USA), Kimberly Hong (San Diego, CA, USA), Matthew Lee (Glasgow, UK), Martin Maron (Boston, MA, USA), Masataka Kawana (Stanford, CA, USA), James Moon (MyCardium AI Ltd, UK), Lisa Salberg (HCMA, USA), Jonathan Schwartz (RocketPharma, USA), Marc Semigran (Edgewise, USA), Maxime Touzot (Owkin, FRA)

Room 4
Tuesday, December 10, 2024
14:00 -16:00

HYPERTROPHIC CARDIOMYOPATHIES (HCM).
Part 2 NEW CHALLENGES FOR FUTURE TRIALS
Chairpersons: Juan Pablo Kaski (London, UK) & Sara Saberi (Ann Arbor, MI,USA)

What is the right background therapy in future trials?
Perry Mark Elliott (London, UK)

What comparators in future trials. What will be standard of care: drug therapy, surgical myectomy and septal ablation?
Milind Desai (Cleveland, OH, USA)

How to assess disease modification? Upstream prevention of progression.
Ethan Rowin (Burlington, MA, USA)

Translating learnings from HCM to HFPEF (and vice versa).
Iacopo Olivotto (Trieste, ITA)

Targeting diastole. Splitting vs lumping hypercontractile states.
Masataka Kawana (Stanford, CA, USA)

Pediatrician's viewpoint.
Juan Pablo Kaski (London, UK)

Industry viewpoint.
Marc Semigran (Edgewise, USA)

Patient's viewpoint.
Lisa Salberg (HCMA, USA)

Regulatory viewpoints.
Hylton Joffe (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate
HYPERTROPHIC CARDIOMYOPATHIES (HCM).
Part 2 DESIGNING FUTURE TRIALS
Chairpersons: Juan Pablo Kaski (London, UK) & Sara Saberi (Ann Arbor, MI,USA)

Panelists: Eric Adler (Lexeo, USA), Arnaud Bastien (BMS, USA), Milind Desai (Cleveland, OH, USA), Perry Mark Elliott (London, UK), Hylton Joffe (FDA, USA), Juan Pablo Kaski (London, UK), Masataka Kawana (Stanford, CA, USA), Matthew Lee (Glasgow, UK),Iacopo Olivotto (Trieste, ITA), Nosheen Reza (Philadelphia, PA, USA), Ethan Rowin (Burlington, MA, USA), Sara Saberi (Ann Arbor, MI,USA), Lisa Salberg (HCMA, USA), Jonathan Schwartz (RocketPharma, USA), Marc Semigran (Edgewise, USA)

Room 4
Tuesday, December 10, 2024
16:30 -18:30

MINERALOCORTICOID RECEPTOR ANTAGONISTS (MRA) CARDIO-KIDNEY THERAPY
Chairpersons: Maria Rosa Costanzo (Naperville, IL, USA) & Jozine Ter Maaten (Groningen, NED)

FINEARTS main results.
Scott Solomon (Boston, MA, USA)
John Mcmurray (Glasgow, UK)

Cardiovascular outcomes with MRA therapy. The totality of evidence.
Faiez Zannad (Paris, FRA)

Kidney outcomes with MRA therapy. The totality of evidence .
Hiddo Heerspink (Groningen, NED)

Statistical viewpoint.
Frank Rockhold (Durham, NC, USA)

Mechanistic insight and plausibility.
Bertram Pitt (Ann Arbor, USA)

Implementing MRA trials results.
How to make sure that MRA therapy is no longer under-used?
Orly Vardeny (Minneapolis, MN, USA)

Industry viewpoints.
Maria Borentain (Bayer, GER), Martin Cowie (AstraZeneca, USA)

Regulatory viewpoints.
Charu Gandotra (FDA, USA)
Gabriella Passacquale (EMA, ITA)

Patient's viewpoint.
Mariette Verbakel (Nijmegen, NED)

The CVCT Multi-Stakeholder Think Tank Debate

MINERALOCORTICOID RECEPTOR ANTAGONISTS (MRA) CARDIO-KIDNEY THERAPY
Chairpersons: Maria Rosa Costanzo (Naperville, IL, USA) & Jozine Ter Maaten (Groningen, NED)

Panelists : Maria Borentain (Bayer, GER), Jawad H Butt (Copenhagen, DEN), Maria Rosa Costanzo (Naperville, IL, USA), Martin Cowie (AstraZeneca, USA), Charu Gandotra (FDA, USA), Hiddo Heerspink (Groningen, NED), Masatake Kobayashi (Tokyo, JPN), John McMurray (Glasgow, UK), Gabriella Passacquale (EMA, ITA), Alexander Peikert (Boston, MA, USA), Bertram Pitt (Ann Arbor, USA), Juergen Prochaska (Boehringer, GER), Frank Rockhold (Durham, NC, USA), Scott Solomon (Boston, MA, USA), Jozine Ter Maaten (Groningen, NED), Orly Vardeny (Minneapolis, MN, USA), Mariette Verbakel (Nijmegen, NED), Faiez Zannad (Paris, FRA)

Room 1
Wednesday, December 11, 2024
08:00 -10:30

ANTI-OBESITY MEDICINES AND CV OUTCOME TRIALS
PART 1 – RESULTS TO DATE AND IMPLICATIONS
Chairpersons: Naveed Sattar (Glasgow, UK) & Benjamin Scirica (Boston, MA, USA)

Why obesity really matters to CV medicine.
Naveed Sattar (Glasgow, UK)

Benefit of lifestyle /surgical interventions weight loss for CV outcomes?
Ian Neeland (Dallas, TX, USA)

SELECT – Summary of all findings to date.
Carolyn Lam (Singapore, SIN)

STEP-HFpEF – SUMMIT and other obesity trials in HF..
Milton Packer (Dallas, TX, USA)

Any evidence for likely CV impact for combination therapy?
Benjamin Scirica (Boston, MA, USA)

Weight loss, sleep apnea and other non-CV outcomes with potential CV consequences.
Subodh Verma (Toronto, CAN)

Statistician's viewpoint.
Frank Rockhold (Durham, NC, USA)

Industry viewpoints: how industry is planning implementation strategies for AOMs?
Maria Sejersten Ripa (Novonordisk, DEN), Masahiro Murakami (Eli Lilly, USA)

Evidence based implementation of anti-obesity drugs. Implications for guidelines and care.
Michael Lincoff (Cleveland, OH, USA)

What OMs in CV medicine exist?
Javed Butler (Dallas, TX, USA)

Health economist and payer's viewpoint: how are regulators responding to results so far.
Benjamin N Rome (Boston, MA, USA)
Borislava Mihaylova (London, UK)

Patient's viewpoint.
Wanda Moore (CCHHE, USA)

The CVCT Multi-Stakeholder Think Tank Debate

ANTI-OBESITY MEDICINES AND CV OUTCOME TRIALS
PART 1 – RESULTS TO DATE AND IMPLICATIONS
Chairpersons: Naveed Sattar (Glasgow, UK) & Benjamin Scirica (Boston, MA, USA)

Panelists: Siddique Abbasi (Amgen, USA), Javed Butler (Dallas, TX, USA), Michael Cooreman (Inventiva, FRA), Josephine Harrington (Durham, NC, USA), Scott Harris (Altimmune, USA), Alessandra Lafranconi (Boehringer, GER), Carolyn Lam (Singapore, SIN), Michael Lincoff (Cleveland, OH, USA), Borislava Mihaylova (London, UK), Wanda Moore (CCHHE, USA), Masahiro Murakami (Eli Lilly, USA) , Ian Neeland (Dallas, TX, USA), Milton Packer (Dallas, TX, USA), Alexander Peikert (Boston, MA, USA), Elke Platz (Boston, MA, USA), Maria Sejersten Ripa (NovoNordisk, DEN), Frank Rockhold (Durham, NC, USA), Benjamin N Rome (Boston, MA, USA), Naveed Sattar (Glasgow, UK), Benjamin Scirica (Boston, MA, USA), Subodh Verma (Toronto, CAN)

Room 1
Wednesday, December 11, 2024
11:00 -13:00

ACUTE DECOMPENSATED HEART FAILURE (ADHF) DRUG AND DEVICE TRIALS
Chairpersons: Daniel Burkhoff (New York, NY, USA) & Maria Rosa Costanzo (Naperville, IL, USA)

Which ADHF patients should be candidates for device therapy trials?
Maria Rosa Costanzo (Naperville, IL, USA)

What is the most relevant primary endpoint in ADHF trials?

Should endpoints in ADHF be specific for device therapies trials?
Javed Butler (Dallas, TX, USA)

ADHF trial: are in-hospital outcomes realistic?
Gad Cotter (Momentum LLC, USA)

Improved decongestion is all what matters!
Biykem Bozkurt (Houston, USA)

Non-MI Pre-Cardiogenic Shock. Failed inotrope trials and potential with istaroxime
Alexandre Mebazaa (Paris, FRA)

How to prevent positive phase 2 trials to lead to neutral phase 3 trials.
Christopher O'Connor (Washington, DC, USA)

Regulatory viewpoints.
Yutaku Kaneta (PMDA, JPN)
Ileana Piña (FDA, USA)

Industry viewpoints.
Philip Adamson (CVRx, USA), Francesca Lawson (Corteria, USA), Peter Muntendam (SQInnovation, USA), Chuck Simonton (Abiomed, USA)

Patient's' viewpoint.
Rhonda Monroe (Baltimore, MD, USA)

The CVCT Multi-Stakeholder Think Tank Debate

ACUTE DECOMPENSATED HEART FAILURE (ADHF) DRUG AND DEVICE TRIALS
Chairpersons: Daniel Burkhoff (New York, NY, USA) & Maria Rosa Costanzo (Naperville, IL, USA)

Panelists: Philip Adamson (CVRx, USA), Daniel Burkhoff (New York, NY, USA), Javed Butler (Dallas, TX, USA), Maria Rosa Costanzo (Naperville, IL, USA), Gad Cotter (Momentum LLC, USA), Andrew Farb (FDA, USA), Philip Janiak (Corteria, FRA), Francesca Lawson (Corteria, USA), Alexandre Mebazaa (Paris, FRA), Rhonda Monroe (Baltimore, MD, USA), Peter Muntendam (SQInnovation, USA), Chris O'Connor (Washington, DC, USA), Joanna Osmanska (Glasgow, UK), Ileana Piña (FDA, USA), Chuck Simonton (Abiomed, USA), Shelly Zieroth (Winnipeg, CAN)

Room 1
Wednesday, December 11, 2024
14:00 -16:00

ANTI-OBESITY MEDICINES AND CV OUTCOMES TRIALS
PART 2– HOW ONGOING AND FUTURE TRIALS ARE ADAPTING TO THE NEW LANDSCAPE
Chairpersons: Javed Butler (Dallas, TX, USA) & Jennifer Green (Durham, NC, USA)

Summary of ongoing CVOTS to report in next 3-4 Years: SURPASS CVOT, SYNCHRONIZE, REDEFINE-3, SURMOUNT MMO, others.
Carolyn Lam (Singapore, SIN)

Mechanistic gaps in effects of AOMs on CV outcomes: weight loss vs other effects?
Naveed Sattar (Glasgow, UK)

Multi-organ imaging. Revealing the cardio-kidney-liver benefits of investigational drugs.
Andrea Dennis (Perspectum, GBR)

How to measure and what are the consequences of muscle loss relative to fat loss?
Jennifer Linge (Amra Medical, SWE)

For how long can placebo-controlled trials of AOMS continue? Time to move to active -control designs?
Jennifer Green (Durham, NC, USA)

Industry viewpoints.
Christian Medom Madsen (Novonordisk, DEN), Mathijs Bunck (Eli Lilly, USA), Elena Startseva (Boehringer, GER)

Regulatory viewpoints.
Bart van der Schueren (EMA, BEL)
Laura Higginbotham (FDA, USA)

NIH viewpoint.
Tiffany Powell-Wiley (NHLBI, NIH, USA)

Patient's viewpoint.
Wanda Moore (CCHHE, USA)

The CVCT Multi-Stakeholder Think Tank Debate

ANTI-OBESITY MEDICINES AND CV OUTCOMES TRIALS
PART 2– HOW ONGOING AND FUTURE TRIALS ARE ADAPTING TO THE NEW LANDSCAPE
Chairpersons: Javed Butler (Dallas, TX, USA) & Jennifer Green (Durham, NC, USA)

Panelists: Siddique Abbasi (Amgen, USA), Jenny Blau (AstraZeneca, USA), Mathijs Bunck (Eli Lilly, USA), Javed Butler (Dallas, TX, USA), Andrea Dennis (Perspectum, GBR),Richard George (Regeneron, USA), Jennifer Green (Durham, NC, USA), Josephine Harrington (Durham, NC, USA), Laura Higginbotham (FDA, USA), Carolyn Lam (Singapore, SIN) , Jennifer Linge (Amra Medical, SWE), Christian Medom Madsen (Novonordisk, DEN), Wanda Moore (CCHHE, USA), Karina Morley (AstraZeneca, SWE), Elke Platz (Boston, MA, USA), Tiffany Powell-Wiley (NHLBI, NIH, USA), Naveed Sattar (Glasgow, UK), Elena Startseva (Boehringer, GER), Bart van der Schueren (EMA, BEL)

Room 1
Wednesday, December 11, 2024
16:30 -18:30

HEART FAILURE NOVEL THERAPIES AND TRIALS
Chairpersons: Mona Fiuzat (Washington, DC, USA) & Alexandre Mebazaa (Paris, FRA)

Soluble Guanylate Cyclase stimulator. VICTOR trial update.
Clara Saldarriaga (Medelin, COL)

New advenues with myosin activation.
Fady Malik (Cytokinetics, USA)

Prednisone – CORTAHF trial.
Jan Biegus (Wroclaw, POL)

Colchicine update.
Jean Claude Tardif (Montreal, CAN)

Targeting Alternative Aldosterone Pathways
John Teerlink (San Francisco, CA, USA)

Targeting systemic inflammation in patients with heart failure through leucocyte immuno-modulation.
Bertram Pitt (Ann Arbor, MI, USA)

The Mega-Elephant in the room in HF trials: should it be mandatory to enroll only patients on optimal evidence-based HF therapies?
Milton Packer (Dallas, TX, USA)

Remote monitoring and AI prediction of HF worsening. How this may be useful for clinical trials.
Jay Edelberg (Prolaio, USA)

The CVCT Multi-Stakeholder Think Tank Debate

HEART FAILURE NOVEL THERAPIES AND TRIALS
Chairpersons : Mona Fiuzat (Washington, DC, USA) & Alexandre Mebazaa (Paris, FRA)

Panelists : Jan Biegus (Wroclaw, POL), Gad Cotter (Momentum LLC, USA), Jay Edelberg (Prolaio, USA), Mona Fiuzat (Washington, DC, USA), Fady Malik (Cytokinetics, USA), Alexandre Mebazaa (Paris, FRA), Atif Mohammad (AstraZeneca, USA), Milton Packer (Dallas, TX, USA), Bertram Pitt (Ann Arbor, MI, USA), Clara Saldarriaga (Medelin, COL), Jean Claude Tardif (Montreal, CAN), John Teerlink (San Francisco, CA, USA)

Room 2
Wednesday, December 11, 2024
08:00 -10:30

TRIGLYCERIDE RICH LIPOPROTEINS TRIALS
Chairpersons: Borge Nordestgaard (Copenhagen, DEN) & Ruth Frikke Schmidt (Copenhagen, DEN)

How to optimize population selection.

Genetic epidemiology.
Borge Nordestgaard (Copenhagen, DEN)

Machine learning identification of rare coding variants.
Ron Do (New York, NY, USA)

Lipid profile of the African patient and need for specific clinical trials.
Abdoul Kane (Dakar, SN)

Prevalence and association of hypertriglyceridemia and obesity associated cardiovascular risk in Middle East
Samir Naeem Assaad (Alexandria, EGY)

Apolipoprotein C3 inhibitors.
For chylomicronemia for prevention of acute pancreatitis.

Anti-sense obligonucleotides
Erik Stroes (Amsterdam, NED)

RNA inhibitors
Robert Rosenson (New York, NY, USA)

For mixed hyperlipidemia in the prevention of CVD.
Christie Ballantyne (Houston, TX, USA)

ANGPTL3 inhibitors. Versatility for the broad spectrum of dyslipidemia.
Robert Rosenson (New York, NY, USA)

Industry viewpoint.
Giacomo Ruotolo (Lilly, USA)

Regulatory viewpoint.
Eileen Craig (FDA, USA)

Patient's viewpoint.
Jacqueline Alikhaani (Los Angeles, USA)

The CVCT Multi-Stakeholder Think Tank Debate
WHAT IS THE BEST TRIGLYCERIDE LOWERING THERAPY FOR THE PREVENTION OF CARDIOVASCULAR EVENTS?
Chairpersons: Borge Nordestgaard (Copenhagen, DEN) & Ruth Frikke Schmidt (Copenhagen, DEN)

Panelists : Jacqueline Alikhaani (Los Angeles, USA), Samir Naeem Assaad (Alexandria, EGY), Christie Ballantyne (Houston, TX, USA), Eileen Craig (FDA, USA), Ron Do (New York, NY, USA), Jennifer Hellawell (Arrowhead Pharmaceuticals, USA), Abdoul Kane (Dakar, SN), Stefan Nilsson (Lipigon Pharmaceuticals, SWE), Borge Nordestgaard (Copenhagen, DEN) , Robert Rosenson (New York, NY, USA), Giacomo Ruotolo (Lilly, USA) , Ruth Frikke Schmidt (Copenhagen, DEN), Erik Stroes (Amsterdam, NED), Xue-Qiao Zhao (Regeneron, USA)

Room 2
Wednesday, December 11, 2024
11:00 -13:00

CLINICAL TRIALS TARGETING LIPOPROTEIN(a) FOR ATHEROSCLEROSIS THERAPY
Chairpersons : Pia Kamstrup (Herlev, DEN) & Robert Rosenson (New York, NY, USA)

Leveraging Lp(a) mechanisms for risk assessment.
Sascha Goonewardena (Ann Arbor, MI, USA)

Differences and similarities among major outcome trials design.

ACCLAIM (Lepodisiran).
Ann Marie Navar (Dallas, TX, USA)

HORIZON
Leslie Cho (Cleveland, OH, USA)

OCEAN(A) update.
Michelle O'Donoghue (Boston, MA, USA)

Promises of an oral inhibitor: Muvalaplin.
Laura Michael (Lilly, USA)

Opportunities with anti-inflammatory therapies.
Wolfgang Koenig (Munich, GER)

Lp(a) gene editing.
Jason Duran (CRISPR Therapeutics)

Regulatory viewpoint.
Rosalyn Adigun (FDA, USA)

Industry viewpoint.
Antonio Lopez (Amgen, USA)

The CVCT Multi-Stakeholder Think Tank Debate

THE CHALLENGES OF A PRIMARY PREVENTION TRIAL FOR LP(A) LOWERING
Chairpersons : Pia Kamstrup (Herlev, DEN) & Robert Rosenson (New York, NY, USA)

Panelists : Rosalyn Adigun (FDA, USA), Leslie Cho (Cleveland, OH, USA), Jason Duran (CRISPR Therapeutics), Sascha Goonewardena (Ann Arbor, MI, USA), Pia Kamstrup (Herlev, DEN), Wolfgang Koenig (Munich, GER), Antonio Lopez (Amgen, USA), Guiomar Mendieta (Madrid, ESP), Laura Michael (Lilly, USA), Ann Marie Navar (Dallas, TX, USA), Michelle O'Donoghue (Boston, MA, USA), Robert Rosenson (New York, NY, USA)

Room 2
Wednesday, December 11, 2024
14:00 -16:00

CHOLESTEROL LOWERING THERAPIES TRIALS
Chairpersons: Wolfgang Koenig (Munich, GER) & Anne Goldberg (St Louis, MO, USA)

ORION-4 and VICTORION-2 PREVENT.
Louise Bowman (Oxford, UK)

PCSK9 interference, progress beyond monoclonal antibodies and RNA inhibitors?
Eric Klug (Sandton, ZAF)

Single-course in vivo gene editing to inactivate PCSK9 and durably lower LDL-C.
Sekar Kathiresan (Verve Therapeutics, USA)

LDL cholesterol lowering with CETP inhibition. Fulfilled expectations?
Anne Goldberg (St Louis, MO, USA)

How special are pediatric trials?
Xue-Qiao Zhao (Regeneron, USA)

Industry viewpoint.
Cesar Cerezo (Novartis, USA), Eva Hurt Camejo (Astra Zeneca, USA), Bruce Given (Arrowhead, USA), John Kastelein (New Amsterdam Pharma, UK)

Regulatory viewpoint.
John Sharretts (FDA, USA)

Patient's viewpoint.
Sadegh Alikhaani (Los Angeles, USA)

The CVCT Multi-Stakeholder Think Tank Debate
HOW DO WE SELECT THE RIGHT CHOLESTEROL LOWERING THERAPY AMONG ALL THE APPROACHES?
Chairpersons: Wolfgang Koenig (Munich, GER) & Anne Goldberg (St Louis, MO, USA)

Panelists : Sadegh Alikhaani (Los Angeles, USA), Cheryl Abbas (Novartis, USA), Louise Bowman (Oxford, UK), Cesar Cerezo (Novartis, USA), Bruce Given (Arrowhead, USA), Anne Goldberg (St Louis, MO, USA), James Hamilton (Arrowhead Pharmaceuticals, USA), Eva Hurt Camejo (Astra Zeneca, USA); John Kastelein (New Amsterdam Pharma, UK), Sekar Kathiresan (Verve Therapeutics, USA), Eric Klug (Sandton, ZAF), Wolfgang Koenig (Munich, GER), Abena Osei-Wusu (Merck, USA), John Sharretts (FDA, USA), Evan Stein (LIB Therapeutics, USA), Xue-Qiao Zhao (Regeneron, USA)

Room 2
Wednesday, December 11, 2024
16:30 -18:30

DELIVERING THE FIRST EFFECTIVE MEDICAL THERAPY FOR AORTIC STENOSIS
Chairpersons: Marc Dweck (Edinburgh, UK) & Sanjay Kaul (Los Angeles, CA, USA)

Aortic stenosis and the need for an effective medical therapy.
Brian Lindman (Nashville, TN, USA)

Potential treatment targets in the valve.
David Newby (Edinburgh, UK)

Targeting the valve- how to design the perfect RCT of a new therapy.
Andres Laguna (Novartis, ESP)

Potential treatment targets in the myocardium.
Paolo Springhetti (Laval, CAN)

Targeting the myocardium- what is the current standard of care & how to design the perfect RCT of a new therapy.
Marc Dweck (Edinburgh, UK)

Medical therapies in aortic stenosis- what the FDA might require for approval.
Charu Gandotra (FDA, USA)

Challenges And Future Opportunities For Conducting Trials Evaluating Medical Therapy For Calcific Aortic Stenosis
Brian Lindman (Nashville, TN, USA)

The CVCT Multi-Stakeholder Think Tank Debate

ACCELERATING APPROVAL OF A FIRST EFFECTIVE MEDICAL THERAPY FOR AORTIC STENOSIS
Chairpersons: Marc Dweck (Edinburgh, UK) & Sanjay Kaul (Los Angeles, CA, USA)

Panelists : Robert Bonow (JAMA Cardiology, USA), Marc Dweck (Edinburgh, UK), Charu Gandotra (FDA, USA), Rebecca Hahn (New York, NY, USA), Andres Laguna (Novartis, ESP), Brian Lindman (Nashville, TN, USA), David Newby (Edinburgh, UK), Mark Petrie (Glasgow, UK), Paolo Springhetti (Laval, CAN), Bernard.Vasseur (FDA, USA)

Room 3
Wednesday, December 11, 2024
08:00 -10:30

iCVCT
HOW TO EVOLVE THE DESIGN OF VALVE TRIALS
Chairpersons: David Cohen (New York, NY, USA) & Stephan Windecker (Bern, CH)

Transcatheter or Surgical Treatment of Aortic-Valve Stenosis. Insight from DEDICTAE
Stefan Blankenberg (Hamburg, GER)

Transcatheter therapies for mitral annular calcification. Debate: do we need a definitive RCT?

Pro: Definitely — Follow the example of TAVR.
Sanjay Kaul (Los Angeles, CA, USA)

Con: are you kidding? All we need is safety data.
Stephan Windecker (Bern, CH)

Structural Heart Trial For Mitral Regurgitation Post Mitra Clip And RESHAPE-HF 2 Trial
Randall Starling (Cleveland, OH, USA)

Transcatheter Valve Replacement in Severe Tricuspid Regurgitation
Rebecca Hahn (New York, NY, USA)

The second wave of transcatheter tricuspid valve trials – population, comparators, and endpoints.
Raul Moreno (Madrid, ESP)

Pre-emptive TAVR: ready for prime time! We have the data!
Marko Banovic (Belgrade, RS)

Pre-emptive TAVR: what's the rush?
Robert Bonow (JAMA Cardiology, USA)

What are the remaining clinical trial questions for TAVR in aortic stenosis?
Stephan Windecker (Bern, CH)

Design Of TAVR trials for aortic insufficiency.
Torsten P Vahl (New York, NY, USA)

Industry viewpoints.
Daniel Wendt (Cytosorbent, USA)

Regulatory viewpoints.
Changfu Wu (FDA, USA)

The iCVCT Multi-Stakeholder Think Tank Debate
HOW TO EVOLVE THE DESIGN OF VALVE TRIALS
Chairpersons: David Cohen (New York, NY, USA) & Stephan Windecker (Bern, CH)

Panelists: Marko Banovic (Belgrade, RS), Stefan Blankenberg (Hamburg, GER), Robert Bonow (JAMA Cardiology, USA) , Daniel Canos (FDA, USA), David Cohen (New York, NY, USA), Marc Dweck (Edinburgh, UK), Aakriti Gupta (Los Angeles, CA, USA), Rebecca Hahn (New York, NY, USA), Sanjay Kaul (Los Angeles, CA, USA), Raul Moreno (Madrid, ESP), John Spertus (Kansas City, MO, USA), Randall Starling (Cleveland, OH, USA), Torsten P Vahl (New York, NY, USA), Daniel Wendt (Cytosorbent, USA), Stephan Windecker (Bern, CH), Changfu Wu (FDA, USA)

Room 3
Wednesday, December 11, 2024
11:00 -13:00

iCVCT
EMERGING ISSUES AND THE FUTURE OF CLINICAL TRIALS IN STRUCTURAL HEART DISEASE
Chairpersons: Rasha al Lamee (London ,UK) & David Cohen (New York, NY, USA)

We need more sham/placebo-controlled trials in structural heart disease.

Pro
Rasha Al Lamee (London, UK)

Con
John Spertus (Kansas City, MO, USA)

Alternatives to Randomized Controlled Trials—When are they reasonable?

Instrumental variable analysis: the case of cerebral embolic protection.
Neel Butala (Denver, CO, USA)

The win ratio should be the preferred method for analyzing clinical trials in structural heart disease

Pro
David Cohen (Boston, MA, USA)

Con
Javed Butler (Dallas, TX, USA)

Industry viewpoint.
Nadim Geloo (Abbott, USA), Janarthanan Sathananthan (Boston Scientific, USA)

Regulatory viewpoints.
Bernard Vasseur (FDA, USA)

HTA viewpoints.
Bart van der Schueren (EMA, BEL)

The iCVCT Multi-Stakeholder Think Tank Debate
EMERGING ISSUES AND THE FUTURE OF CLINICAL TRIALS IN STRUCTURAL HEART DISEASE
Chairpersons: Rasha al Lamee (London, UK) & David Cohen (New York, NY, USA)

Panelists: Rasha al Lamee (London, UK), Neel Butala (Denver, CO, USA), Javed Butler (Dallas, TX, USA), Daniel Canos (FDA, USA), David Cohen (New York, NY, USA), Ahmed Kolkailah (Dallas, TX, USA), John Laschinger (Edwards, USA), Jeff Popma (Medtronic, USA), Janarthanan Sathananthan (Boston Scientific, USA), John Spertus (Kansas City, MO, USA), Bernard Vasseur (FDA, USA), Bart van der Schueren (EMA, BEL), Bernard Vasseur (FDA, USA), Robert Yeh (Boston, MA, USA), Bram Zuckerman (FDA, USA)

Room 3
Wednesday, December 11, 2024
14:00 -16:00

iCVCT
SHOCK MECHANICAL CIRCULATORY SUPPORT TRIALS
Chairpersons: Holger Thiele (Leipzig, GER) & Robert Yeh (Boston, USA)

DanGer – generalizability of results in contemporary practice
Holger Thiele (Leipzig, GER)

Design of future post-MI shock trials of mechanical support – exclusions, endpoints, control group.
Navin Kapur (Boston, MA, USA)

What is the regulatory pathway for mechanical circulatory support devices for cardiogenic shock after DanGer?
Changfu Wu (FDA, USA)

Real World Evidence to support mechanical circulatory support device evaluation.
Robert Yeh (Boston, MA, USA)

Industry vision for the future of mechanical circulatory support devices in cardiogenic shock.
Chuck Simonton (Abiomed, USA), Nitin Salunke (Supira Medical, USA), Janarthanan Sathananthan (Boston Scientific, USA)

HTA viewpoints.
TBD

The iCVCT Multi-Stakeholder Think Tank Debate
SHOCK MECHANICAL CIRCULATORY SUPPORT TRIALS
Chairpersons: Holger Thiele (Leipzig, GER) & Robert Yeh (Boston, USA)

Panelists: Daniel Burkhoff (New York, NY, USA), Chuck Simonton (Abiomed, USA), Navin Kapur (Boston, MA, USA), Nitin Salunke (Supira Medical, USA), Janarthanan Sathananthan (Boston Scientific, USA), Holger Thiele (Leipzig, GER), Changfu Wu (FDA, USA), Robert Yeh (Boston, MA, USA)

Room 3
Wednesday, December 11, 2024
16:30 -18:30

iCVCT
CORONARY INTERVENTION TRIALS
PROMOTING INNOVATION AND IMPROVING PATIENTS ACCESS
Chairpersons: Don Cutlip (Boston, MA, USA) & Roxana Mehran (New York, NY, USA)

Review of clinical trial designs for intra-stent restenosis indication.
Robert Yeh (Boston, MA, USA)

Clinical trial designs for coronary drug-coated and eluting balloons de novo indications.
Ron Waksman (Washington, DC, USA)

Is it time to move to hierarchical composite?
Milton Packer (Dallas, TX, USA)

How should clinical trials assess PCI effectiveness?
Are peri-procedural MI and target lesion revascularization still the right metrics?
Lydia Glaw (FDA, USA)

Should angina based quality of life measures be included?
Rasha Al-Lamee (London, UK)

RWD on the use of drug-coated balloon in gulf states .
Abdullah Shehab (Al Ain, UAE)

Regulatory viewpoints.
Mark Chakravarty (NICE, UK)

Industry viewpoints.
Dom Alloco (Shockwave Medical, USA), Lance Bates (Boston Scientific, USA), Ethan Korngold (Abbott, USA)

The iCVCT Multi-Stakeholder Think Tank Debate
CORONARY INTERVENTION TRIALS
HOW CAN WE INCENTIVIZE INNOVATION AND IMPROVE SUSTAINABLE ACCESS FOR PATIENTS?
Chairpersons: Don Cutlip (Boston, MA, USA) & Roxana Mehran (New York, NY)

Panelists: Rasha Al-Lamee (London, UK), Dom Alloco (Shockwave Medical, USA), Lance Bates (Boston Scientific, USA), Sinjini Biswas (Melbourne, AUS), Mark Chakravarty (NICE, UK), Don Cutlip (Boston, MA, USA), Andrew Farb (FDA, USA), Lydia Glaw (FDA, USA), Ethan Korngold (Abbott, USA), Roxana Mehran (New York, NY), Milton Packer (Dallas, TX, USA), Abdullah Shehab (Al Ain, UAE), Ron Waksman (Washington, DC, USA), Robert Yeh (Boston, MA, USA)

Room 4
Wednesday, December 11, 2024
08:00 -10:30

GLOBAL REGULATORY SUMMIT
HOW TO PROMOTE INCLUSIVENESS AND ACCELERATE APPROVAL OF EVIDENCE BASED CARDIOVASCULAR THERAPY GLOBALLY
Chairpersons: Robert Califf (FDA, USA) & Faiez Zannad (Paris, FRA)

The ever rising global burden of CV disease.
Nawab Qizilbash (Madrid, ESP)

Variations in geographical variations of CV risk and disease. Global Burden of Disease vs., InterHeart - PURE vs., The Global Cardiovascular Risk Consortium
Christina Magnussen (Hamburg, GER)

Issues with geographical subgroup analyses in clinical trials. Is it geography or level/inequality of income?
Muthiah Vaduganathan (Boston, MA, USA)

Is applying for approval of CV common diseases drugs declining globally?
Claus Bolte (Ex-Swissmedic, Basel, CH)

Issues with global generalizability of Western-generated evidence.
Faiez Zannad (Paris, FRA)

How to make cardiology clinical trials more inclusive
Harriette Van Spall (Hamilton, ON, CAN)

Training And Clincial Research Capacity Building In Low And Medium Income Countries. Unmet Needs and potential Solutions
Chadli Dziri (Tunis, TUN)

Industry viewpoints.
Jyothis George (Amgen, USA), Brad Horst (Boston Scientific, USA)

Regional regulatory viewpoints.
Mirvat Alasnag (Saudi FDA, KSA)
Yutaku Kaneta (PMDA, JPN)
Xiaodong Guan (Beijing, CHN)
Mohamed Sobhy (Alexandria, EGY)

The CVCT Multi-Stakeholder Think Tank Debate

GLOBAL REGULATORY SUMMIT
HOW TO PROMOTE INCLUSIVENESS AND ACCELERATE APPROVAL OF EVIDENCE BASED CARDIOVASCULAR THERAPY GLOBALLY
Chairpersons: Robert Calif (FDA, USA), Faiez Zannad (Paris, FRA)

Panelists : Anubha Agarwal (St Louis, MI, USA), Mirvat Alasnag (Saudi FDA, KSA), Sangeetha Anand (CSL Vifor, SWI), Claus Bolte (Ex-Swissmedic, Basel, CH), Robert Califf (FDA, USA), Chadli Dziri (Tunis, TUN), Steven Lok Fai Cheang (Nanjing, CHN), Habib Gamra (Sousse, TN), Liming Gan (Ribocure Pharmaceuticals, CHN), Jyothis George (Amgen, USA), David Goff (NHLBI, NIH, USA), Xiaodong Guan (Beijing, CHN), Christine Gouillard (USAI2, Singapore, SIN), Brad Horst (Boston Scientific, USA), Chokri Jeribi (Eshmoun, TUN), Yutaku Kaneta (PMDA, JPN), Kazuomi Kario (Tochigi, JPN), Charles Lee (AstraZeneca, USA) , Xinli Li (Nanjing, CHN), Renato Lopes (Durham, NC, USA), Christina Magnussen (Hamburg, GER), Felipe Martinez (Cordoba, ARG), Manabu Minami (PMDA, JPN), Qizilbash (Madrid, ESP), Azza Saleh (Cairo, EGY), Abdullah Shehab (Al Ain, UAE), Mohalmed Sobhy (Alexandria, EGY), Muthiah Vaduganathan (Boston, MA, USA), Brian Wiliams (British Heart Foundation, UK), Harriette Van Spall (Hamilton, ON, CAN), Lijing Yan (Kunshan, CHN), Fred Yang (KBP BioScience, USA), Faiez Zannad (Paris, FRA), Sophia Zoungas (Melbourne, AUS)

Room 4
Wednesday, December 11, 2024
11:00 -13:00

PATIENT TRIALISTS MEET CLINICAL TRIALISTS.
"The impact of Health Data and Digital Tools from clinical trials to results in treatments"
Chairpersons: Penilla Gunther (FOKUS,Patient, Stockholm, SWE) & Greg Merritt (Patient Is Partner, Brighton, USA)

Welcome
Penilla Gunther (FOKUS Patient, Stockholm, SWE) & Greg Merritt (Patient Is Partner, Brighton, USA)

Introduction part 1
The importance of understanding and agreement for usage of Health Data
An example from Europe - The European Health Data Space - EHDS
Penilla Gunther (FOKUS Patient, Stockholm, SWE)

How to build clinical trials with the usage of AI
Bram Ramjiawan (Winnipeg, CAN)

Patient Panel Discussion – Response to Speakers
Jerker Liljestrand (Stockholm, SWE), Magdalena Daccord (FH Europe, CH)

Introduction part 2
Do Digital Culture and Maturity Within Patient Groups Matters for Global Trials
Mellanie True Hills (Stop AFib, USA)

How to implement digital clinical trials to include more patients
The owner of Patient data in clinical trials – a European and American perspective
TBD

Sharing Trial Results with Patient Participants. How is this Done Across The Globe?
Jennifer Costello (Bristol-Myers-Squibb, USA)

Patient panel discussion – response to speakers
Celina Gorre (Women at Heart, USA)
Nick Hartshorne-Evans (Pumping Marvellous Foundation, UK)
Magdalena Daccord (FH Europe, CH)

Questions from the audience

Summary
Penilla Gunther (FOKUS Patient, Stockholm, SWE) & Greg Merritt (Patient is Partner, USA)

The CVCT Multi-Stakeholder Think Tank Debate

LISTEN TO PATIENT TRIALISTS VOICE
HOW TO FACILITATE PATIENT ACCEPTANCE TO BE ENROLLED IN TRIALS
ACCESS TO HEALTH DATA FROM CLINICAL TRIALS – WHO OWNS THE DATA?
Chairpersons: Penilla Gunther (FOKUS,Patient, Stockholm, SWE) & Greg Merritt (Patient Is Partner, Brighton, USA)

Panelists : Bram Ramjiawan (Winnipeg, CAN), Jennifer Costello (Bristol-Myers-Squibb, USA), Magdalena Daccord (FH Europe, CH), Penilla Gunther (FOKUS,Patient, Stockholm, SWE), Celina Gorre (Women at Heart, USA), Nick Hartshorne-Evans (Pumping Marvellous Foundation, UK) , Jerker Liljestrand (Stockholm, SWE), Greg Merritt (Patient Is Partner, Brighton, USA); Mellanie True Hills (Stop AFib, USA), Ron Winslow (Ex Wall Street Journal, USA)

Room 4
Wednesday, December 11, 2024
14:00 -16:00

UNDIAGNOSED HEART FAILURE
WHY WE SHOULDN'T WAIT FOR PATIENTS TO COME TO US?
Chairpersons: Nick Hartshorne Evans (Preston, UK) & Rajiv Sankaranarayanan (Liverpool, UK)

BEAT HF – A Disease Awareness Campaign, BEAT to TREAT and Mass Screening – The Why's How's and What's
Nick Hartshorne-Evans (Pumping Marvellous Foundation, UK)

Results from the National BEAT- HF screening campaign and moving towards BEAT to TREAT.
Rajiv Sankaranarayanan (Liverpool, UK)

Results from Everton one-stop breathlessness hu.
Rajiv Sankaranarayanan (Liverpool, UK)

Wait for Echo - Revolution HF.
Lisa Anderson (London, UK)

Quick AI Echo HF diagnosis in BEAT TO TREAT.
Christine Gouillard (US2AI, SIN)

Bridging the findings BEAT TO TREAT with the STRONG HF findings.
Start early and move fast?
Alexandre Mebazaa (Paris, FRA)

Is BEAT TO TREAT replicable in other health care systems?
Nicolas Girerd (Nancy, FRA), Ambarish Pandey (Dallas, TX, USA)

Industry viewpoints.
Martin Cowie (Astrazeneca, UK), Serge Masson (Roche, CH)

The CVCT Multi-Stakeholder Think Tank Debate
PROACTIVE MANAGEMENT OF UNDIAGNOSED AMBULATORY HEART FAILURE.
Chairpersons: Nick Hartshorne Evans (Preston, UK) & Rajiv Sankaranarayanan (Liverpool, UK)

Panelists : Lisa Anderson (London, UK), Ankeet Bhatt (Boston, MA, USA), Martin Cowie (AstraZeneca, UK), Nicolas Girerd (Nancy, FRA), Christine Gouillard (US2AI, SIN),Nick Hartshorne-Evans (Pumping Marvellous Foundation, UK), Serge Masson (Roche, CH), Alexandre Mebazaa (Paris, FRA), Ambarish Pandey (Dallas, TX, USA),Rajiv Sankaranarayanan (Liverpool, UK), Shelly Zieroth (Winnipeg, CAN)

Room 4
Wednesday, December 11, 2024
16:30 -18:30

BIOMARKER GUIDED DRUG DEVELOPMENT

Chairpersons : Kirkwood Adams (Chapel Hill, NC, USA) & Jim Januzzi (Boston, MA, USA)

How to make a good use of biobanks collected during clinical trials?
Faiez Zannad (Paris, FRA)

Proteomic studies for drug discovery using trial bio-samples.
Jasper Tromp (Singapore, SIN)

Biomarkers utilization in clinical trial for risk enrichment and/or enrollment of potential responders.
Brendan M. Everett (Boston, MA, USA)

Biomarker data from clinical trials for MOA investigation and for identification of potential druggable targets.
TBD

What will it take to bring natriuretic peptides to the level of regulatory tool?
Jim Januzzi (Boston, MA, USA)

Industry viewpoints.
Gillian Murtagh (Abbott, UK), Karsten Strauß (Olink, SWE)

Regulatory viewpoints.
Jeff Siegel (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Debate

BIOMARKER GUIDED DRUG DEVELOPMENT

Chairpersons : Kirkwood Adams (Chapel Hill, NC, USA) & Jim Januzzi (Boston, MA, USA)

Panelists : Joe Gogain (Somalogic, USA), Brendan M. Everett (Boston, MA, USA), Christian Hunter (Abbott, USA), Jim Januzzi (Boston, MA, USA), Gillian Murtagh (Abbott, UK), Jule Pinter (Würzburg, GER), Jeff Siegel (FDA, USA), Mikhail Sumin (Boehringer Ingelheim, GER), Karsten Strauß (Olink, SWE), Jasper Tromp (Singapore, SIN), Faiez Zannad (Paris, FRA)